Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome by Parrini, Martina et al.
1SCIENTIFIC REPORTS????? 16825 ??? ?????????????????????????????
????????????????????????????????
Aerobic exercise and a BDNF-
mimetic therapy rescue learning 
and memory in a mouse model of 
Down syndrome
Martina Parrini?, Diego Ghezzi  ???, Gabriele Deidda???, Lucian Medrihan???, Enrico 
????????????, Micol Alberti?, Pietro Baldelli  ???, Laura Cancedda  ? & Andrea Contestabile  ?
????????????????????????????? ??????????????????? ?? ?????????????????????????????????????? ????
??????????????????????? ??????????????? ??????????? ???????????? ?????? ????? ???????? ?????????????????
??????????????????????????????????????????????? ???????????? ?????? ??????????????? ????????????????
? ??????????????? ?????????????????? ??????????????? ?????? ??????????????? ????????????????????
????????? ??????????????????????????????? ????????????????????????????????????????????? ????
? ???????????????????????????????????????????????????????????? ?? ??????????????????????????????????
??????????????????????????????????????????????????????????????????? ????? ????????????????????????????
??? ????????????? ?????????????????????????? ??? ???????? ???????????????? ??????????? ???????????
????? ??? ???????????????????????????????????? ?????????????? ???????????? ???????????????????????????
?????? ???????????????????????????????? ???? ?????? ??????????????? ???????????????????????????
????????????????????????? ??????????????????? ?? ?????? ?????????????????? ???????? ?? ??????????????
???????????????????????????????? ?????? ?????????? ?????? ????? ????? ?????? ???????? ?????? ????
???????????????????????????? ???????????????? ????????????????????? ???????????????????????? ????
signaling represents a potentially new pharmacological target for treatments aimed at rescuing 
?????????? ???????????????????????? ???? ??
Down syndrome (DS) is the main cause of genetically dened intellectual disability, with an estimated frequency 
of 1 in every 1000 live births1. Intellectual disabilities represent the major hallmark of DS and are characterized 
by a low Intelligence Quotient (IQ), as well as learning and memory decits in dierent cognitive domains1–4. e 
Ts65Dn mouse is the best characterized and most widely used animal model of DS. It carries a freely segregating 
extra chromosome bearing the triplication of the distal segment of mouse chromosome 16, which is syntenic to 
part of the long arm of human chromosome 215. e Ts65Dn mouse recapitulates many aspects of DS, including 
cognitive impairment and altered hippocampus-dependent memory function5–7. Although the Ts65Dn model 
presents some genetic limitations due to partial triplication of human chromosome 21 (HSA21) orthologous 
genes and the concurrent triplication of some non-HSA21 genes8, it recapitulates many of the phenotypic features 
of the human syndrome and is currently the only mouse model used for preclinical identication of pharmaco-
logical interventions targeting cognitive impairments in DS9. A number of mechanisms underlying these cogni-
tive hallmarks have been identied in Ts65Dn mice, including an imbalance between excitatory and inhibitory 
neurotransmission10–19, impairment of hippocampal synaptic plasticity6,11,20 and a decrease in adult neurogenesis 
in the hippocampal dentate gyrus (DG)6,21.
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According to previous studies of both rodents and humans, aerobic exercise induces a wide range of benecial 
eects on brain neurophysiology, including enhanced expression of neurotrophins, increased hippocampal vol-
ume and improved cognitive performance22–39. e benecial eects of aerobic exercise have been associated with 
the upregulation of BDNF expression, increased adult neurogenesis in the hippocampal DG and potentiation 
of synaptic plasticity23–25,29–33,40–48. Indeed, among the many molecular players involved in the positive eect of 
exercise, BDNF signaling through its tropomyosin-receptor-kinase B (TrkB) receptor is known to play a pivotal 
role in both enhanced brain plasticity and cognition47,49–52. Moreover, many studies have highlighted BDNF/TrkB 
signaling as a main regulator of long-term potentiation (LTP, a well characterized model of synaptic plasticity) 
at hippocampal Schaer collateral-CA1 synapses53–55, hippocampus-dependent cognition and learning56–62 and 
the maturation and integration of DG newborn neurons into the hippocampal circuit63,64. Interestingly, dier-
ent manipulations that are able to rescue learning decits in Ts65Dn mice are associated with increased BDNF 
expression17,65–67, indicating a possible common mechanism of action through the modulation of the neurotro-
phin system.
Here, we report a detailed biochemical, structural, electrophysiological and behavioral assessment of the pos-
itive eect of aerobic exercise on the corresponding decits observed in trisomic animals, indicating that exercise 
is a valuable tool to promote brain plasticity and possibly represents a complementary therapeutic approach to 
pharmacologic interventions in patients with DS. Interestingly, BDNF expression was substantially decreased in 
the hippocampus of patients with DS, and exercise increased BDNF expression in trisomic animals. erefore, we 
investigated the use of a possible pharmacological approach intended to promote BDNF signaling in patients with 
DS and provide evidence that the treatment of Ts65Dn mice with the BDNF-mimetic drug 7,8-dihydroxyavone 
(DHF), completely rescued learning and memory impairments. us, we identied a new pharmacological target 
to treat DS-associated cognitive impairment.
Results
In this study, we aimed to investigate the eects of strategies that stimulate brain neuroplasticity mechanisms on 
the rescue of learning and memory decits observed in the Ts65Dn mouse model of DS. To accomplish this goal, 
we rst took advantage of voluntary exercise, a paradigm known to promote plastic changes and exert benecial 
eects on several neurochemical and functional aspects of both the human and rodent brains22–24. We hypothe-
sized that aerobic exercise stimulates dierent neurophysiological processes in the trisomic brain, including adult 
neurogenesis, synaptogenesis, synaptic plasticity and neurotrophin expression. We provided adult Ts65Dn male 
mice and wild-type (WT) littermates (4-5 month-old) with free access to running wheels for 4 weeks to assess 
the eects of physical exercise on these dierent processes and on cognitive functions in the mouse model of 
DS (Fig. 1A). Control (sedentary) mice were housed in standard cages without running wheels. Both WT and 
Ts65Dn mice in the running group (exercise) showed strong running activity that was slightly, but signicantly, 
higher for trisomic animals (WT: 4.33 ± 1.08 Km/day, n = 14; Ts65Dn: 5.56 ± 0.80 Km/day, Fig. 1A).
?????????????????????????????????????? ????????????????? ?????? ????? Based on accumulat-
ing evidence, physical exercise induces specic changes in neural function and enhances learning and memory, 
particularly hippocampus-dependent behaviors. According to previous behavioral studies, Ts65Dn mice exhibit 
learning and memory decits in several behavioral tasks5–7,10. We tested Ts65Dn mice in a battery of behavioral 
tests to evaluate the long-term eects of aerobic exercise on dierent cognitive domains. Importantly, the exercise 
paradigm did not cause a general enhancement of motor performance (Supplementary Fig. 1) that could interfere 
with the evaluation of cognitive functions. We rst used the contextual fear conditioning (CFC) test to evaluate 
associative memory. Consistent with the results from previous studies6,7, sedentary Ts65Dn mice showed a strong 
reduction in the freezing response upon re-exposure to the adverse contest 24 hours aer conditioning, indicating 
an impairment in associative learning in this test. Interestingly, exercise completely restored associative learning 
in Ts65Dn mice (Fig. 1B), without inducing changes in non-associative freezing (i.e., exposure to a new context) 
or altering sensitivity to the shock (Supplementary Fig. 2A).
Next, we evaluated the eect of exercise on spatial memory with the object location (OL) test. In this test, mice 
must discriminate the new location of a familiar object in relation to the available spatial information. Sedentary 
Ts65Dn mice were unable to identify the new location aer a retention period of 24 hours. However, aer 4 
weeks of exercise, the performance of Ts65Dn mice was indistinguishable from WT mice, indicating the complete 
recovery of spatial memory in trisomic animals (Fig. 1C). Next, we used the novel object recognition (NOR) test 
to evaluate long-term discriminative memory. As expected, sedentary Ts65Dn mice were unable to discriminate 
the new object, but performed as well as sedentary WT mice following the exercise paradigm (Fig. 1D). Notably, 
and consistent with other reports, exercise enhanced novel object recognition memory in WT mice68,69. e eect 
of exercise on Ts65Dn mice in both OL and NOR tests was independent of the preference for a dierent object 
(Supplementary Fig. 2B,C).
??????????????????????????????????????????????????????????????????????? ?????? ????? Adult 
neurogenesis in the DG is involved in hippocampus-dependent memory functions70 and is known to be regulated 
by a variety of factors, such as age, stress, exercise, environment, learning, and seizures46,48,70–72. In particular, 
voluntary wheel-running robustly enhances cell proliferation and the number of newly generated neurons in 
the dentate subgranular zone (SGZ) of the hippocampus43,46,48. Since hippocampal cell proliferation and neu-
rogenesis are impaired in adult Ts65Dn mice6,21, we thus assessed whether voluntary aerobic exercise positively 
impacted adult hippocampal neurogenesis in Ts65Dn mice. We rst evaluated the proliferation of neural pro-
genitor cells (NPCs) in the DG by labeling dividing cells with the thymidine analog 5-bromo-2-deoxyuridine 
(BrdU) during the last week of wheel running exercise (Fig. 2A). As expected, the number of BrdU-positive cells 
(BrdU+) cells was substantially decreased in sedentary Ts65Dn mice compared to WT mice, consistent with a 
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Figure 1. Physical exercise improved cognitive decits in Ts65Dn mice. (A) Le, schematic representation 
of the experimental protocol. Right, average daily distance travelled by WT and Ts65Dn mice in the running 
group. #P = 0.033 Mann-Whitney Test. (B) Top, schematic representation of the contextual fear conditioning 
test. Le, sedentary Ts65Dn mice showed a strong reduction in freezing response in the context test, indicative 
of impaired associative learning. Physical exercise completely restored contextual learning in trisomic mice. 
Two-way ANOVA: genotype [F1,45 = 1.353, P = 0.251]; treatment [F1,45 = 9.512, P = 0.003]; genotype x 
treatment [F1,45 = 9.322, P = 0.004]. Right, both WT and Ts65Dn mice showed negligible freezing response 
when exposed to a new context. (C) Top, schematic representation of the object location (OL) test. Bottom, four 
weeks of physical exercise rescued spatial memory in Ts65Dn mice in the OL test. Two-way ANOVA: genotype 
[F1,51 = 14.187, P < 0.001]; treatment [F1,51 = 19.382, P < 0.001]; genotype x treatment [F1,51 = 12.787, P < 0.001]. 
(D) Top, schematic representation of the novel object recognition (NOR) test. Bottom, four weeks of physical 
exercise rescued novelty discrimination decits in Ts65Dn mice in the NOR test. Two-way ANOVA: genotype 
[F1,61 = 8.856; P = 0.004]; treatment [F1,61 = 13.114; P < 0.001]; genotype x treatment [F1,61 = 0.503; P = 0.481]. 
For all panels the number in parenthesis indicates the number of animals tested for each experimental group. 
*P < 0.05, **P < 0.01, ***P < 0.001, Tukey post hoc test following two-way ANOVA.
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Figure 2. Voluntary exercise restored functional adult neurogenesis in the DG of Ts65Dn mice. (A) 
Schematic representation of the experimental protocol and BrdU administration to label proliferating cells. 
(B) Representative confocal z-stack projection images showing immunostaining for BrdU (green), DCX (red) 
and the pan-neuronal marker NeuN (blue). Scale bar: 50 µm. e insert on the upper-le corner of each image 
shows a detail of BrdU staining in the area indicated by the dashed rectangle. (C) Quantitative analyses of 
BrdU+ cells found 24 h post BrdU administration in sedentary or running Ts65Dn and WT mice. Proliferation 
of neural precursor cells was fully rescued by exercise in Ts65Dn mice. Two-way ANOVA: genotype 
[F1,23 = 10.967, P = 0.003]; treatment [F1,23 = 11.391, P = 0.003]; genotype x treatment [F1,23 = 0.0000291, 
P = 0.996]. (D) Quantitative analysis of DCX+ cells in sedentary or running Ts65Dn and WT mice. Numbers 
of DCX+ immature newborn neurons were totally restored in Ts65Dn mice by running. Two-way ANOVA: 
genotype [F1,23 = 10.244, P = 0.004]; treatment [F1,23 = 10.480, P = 0.004]; genotype x treatment [F1,23 = 0.0455, 
P = 0.833]. (E) Schematic representation of the experimental protocol for BrdU pulse-chase experiments. (F) 
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proliferation decit in trisomic adult NPCs6,21. However, aerobic exercise induced a 2-fold increase in the number 
of BrdU+ cells in the DG of Ts65Dn mice and also substantially increased proliferation in WT littermates (+50%) 
(Fig. 2B,C). Accordingly, an immunohistochemistry analysis of the population of adult-generated newborn neu-
rons for the early neuronal marker doublecortin (DCX)73 showed a signicant reduction in the number of DCX+ 
newborn neurons in the DG of sedentary Ts65Dn mice that was completely restored to levels comparable with 
sedentary WT littermates following exercise (Fig. 2B–D). In addition, quantication of the long-term survival of 
newly generated cells and their dierentiation toward the neuronal lineage using BrdU pulse-chase experiments 
(Fig. 2E) revealed that the number of BrdU+ cells that were double-labeled with the mature neuronal marker 
NeuN (BrdU+/NeuN+) 4 weeks aer BrdU administration was signicantly reduced in sedentary Ts65Dn mice. 
However, the number of BrdU+/NeuN+ cells increased in both WT and Ts65Dn mice following running training 
(Fig. 2F,G). Moreover, the phenotypic analysis revealed that the percentage of BrdU+/NeuN+ cells among the 
total number of BrdU+ cells was similar in all groups, indicating that the commitment toward the neuronal line-
age was virtually unaected (Fig. 2H). Based on these data, aerobic exercise eciently restored adult neurogenesis 
defects in Ts65Dn mice essentially by rescuing defective NPC proliferation.
We next examined a form of long-term potentiation at medial perforant path (MPP) synapses onto dentate 
granule neurons (DG-LTP, Fig. 2I), which is known to depend on adult-generated newborn neurons74–77, to assess 
the functional integration of adult-born neurons in Ts65Dn mice following exercise. As shown in our previous 
study, this bona de form of neurogenesis-dependent synaptic plasticity is absent in Ts65Dn mice due to impaired 
adult neurogenesis and a decreased supply of newborn neurons6. According to previous studies, high frequency 
stimulation (HFS) of the MPP readily induced DG-LTP in WT slices6,74–76, but failed to potentiate slices from 
Ts65Dn mice (Fig. 2J,K). Physical exercise completely restored DG-LTP in Ts65Dn mice (+19%) to levels similar 
to their sedentary WT littermates. Physical exercise also slightly, but signicantly, increased DG-LTP in WT mice 
(+7%). us, physical exercise rescued functional adult neurogenesis in the DG of Ts65Dn mice.
????????????????????????????????????????????? ?????? ????? We next evaluated possible eects of 
exercise on non-neurogenic regions of the trisomic brain. erefore, we rst recorded spontaneous miniature 
excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs, respectively) by obtaining whole-cell 
patch-clamp recordings from hippocampal CA1 pyramidal neurons. Miniature synaptic events (recorded in the 
presence of the voltage-gated sodium channel blocker TTX to prevent action potential ring) reect the sponta-
neous quantal release of neurotransmitters from all presynaptic terminals converging on the recorded neuron. 
e frequency of these events is proportional to the total number of presynaptic terminals on the patched neuron 
and the probability of release at each terminal. In sedentary Ts65Dn mice, the mEPSC frequency was signicantly 
reduced, indicating a presynaptic impairment at glutamatergic terminals. Interestingly, the mEPSC frequency 
was fully restored by exercise in Ts65Dn mice to a level comparable to WT mice (Fig. 3A,B). e change in the 
frequency was not accompanied by an alteration in the amplitude of these events, suggesting that postsynaptic 
glutamatergic receptors functioned normally in Ts65Dn mice. In contrast, the mIPSC frequency was similar 
between sedentary WT and Ts65Dn pyramidal CA1 neurons, but it was signicantly reduced by running in 
both genotypes, without detectable changes in amplitude, consistent with previous reports78 (Fig. 3C,D). ese 
electrophysiological results revealed a previously unrecognized synaptic decit that was specic for glutama-
tergic synapses in the trisomic CA1 eld and was eectively rescued by exercise. In particular, the decrease in 
mEPSC frequency suggests a decrease in the number of glutamatergic synapses in Ts65Dn hippocampus. We 
evaluated the density of glutamatergic and GABAergic synapses in the hippocampal CA1 stratum radiatum by 
immunostaining for the specic presynaptic markers vGLUT1 (vesicular glutamate transporter 1) and vGAT 
(vesicular GABA transporter), respectively, to elucidate this hypothesis. Consistent with the observed decrease in 
mEPSC frequency, the density of vGLUT1-positive puncta was decreased in sedentary Ts65Dn mice, indicating 
a substantial paucity of glutamatergic synapses. Remarkably, aerobic exercise completely restored the density 
vGLUT1-positive puncta in Ts65Dn mice and signicantly decreased the density of vGAT-positive puncta in 
both WT and Ts65Dn mice (Fig. 3E–G), indicating that exercise extensively regulated synaptogenesis. Moreover, 
an ultrastructural morphometric analysis using transmission electron microscopy (TEM) showed that the den-
sity of total synaptic vesicles (SVs) and the synaptic bouton area were similar in all experimental groups for 
both asymmetric (glutamatergic) and symmetric (GABAergic) synapses (Supplementary Fig. 3). Conversely, the 
length of the active zone (AZ) in asymmetric synapses was increased by exercise in both genotypes, whereas the 
Representative confocal z-stack projection images showing immunostaining for BrdU (green), NeuN (red) and 
GFAP (blue) on brain slices from mice sacriced 4 weeks aer BrdU administration. Scale bar: 50 µm. (G) e 
number of new neurons (BrdU+/NeuN+) found 4 weeks aer BrdU administration was rescued by exercise 
in Ts65Dn mice. Two-way ANOVA: genotype [F1,27 = 5.123, P = 0.032]; treatment [F1,27 = 22.833, P < 0.001]; 
genotype x treatment [F1,27 = 4.871, P = 0.036]. (H) Percentage distribution of BrdU
+/NeuN+, BrdU+/GFAP+, 
and BrdU+ only-labeled cells found 4 weeks aer BrdU administration. No statistical dierence was found 
between the experimental groups. (I) Schematic representation of the experimental protocol and positioning of 
stimulating and recording electrodes in hippocampal circuit for DG-LTP. (J) Average time course of the increase 
in the slope of eld excitatory postsynaptic potentials (fEPSP) elicited in the DG medial molecular layer aer 
stimulation of the MPP in hippocampal slices obtained from Ts65Dn and WT mice. (K) Quantication of LTP 
elicited in the DG of WT and Ts65Dn mice. Two-way ANOVA: genotype [F1,23 = 60.530, P < 0.001]; treatment 
[F1,23 = 79.844, P < 0.001], genotype x treatment [F1,23 = 15.859, P < 0.001]. Number in parenthesis indicates the 
number of samples analyzed for each experimental group. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey post hoc 
test following two-way ANOVA.
www.nature.com/scientificreports/
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Figure 3. Physical exercises rescues synaptic decits in Ts65Dn mice. (A) Representative traces showing 
spontaneous miniature excitatory postsynaptic currents (mEPSC) recorded from CA1 pyramidal neurons 
of WT and Ts65Dn mice in the presence of GABA receptors blockers. (B) mEPSC frequency was reduced in 
sedentary Ts65Dn mice and fully restored by physical exercise. Two-way ANOVA: genotype [F1,25 = 0.0361, 
P = 0.851]; treatment [F1,25 = 5.076, P = 0.033]; genotype x treatment [F1,25 = 8.018, P = 0.009]. mEPSCs 
amplitude was not signicantly dierent across experimental groups. (C) Representative traces showing 
spontaneous miniature inhibitory postsynaptic currents (mIPSC) recorded from CA1 pyramidal neurons of 
WT and Ts65Dn mice in the presence of glutamate receptors blockers. (D) mIPSC frequency was reduced by 
running in both WT and Ts65Dn mice. Two-way ANOVA: [F1,26 = 0.0497, P = 0.825]; treatment [F1,26 = 14.628, 
P < 0.001]; genotype x treatment [F1,26 = 0.0348, P = 0.854]. mIPSC amplitude was not signicantly dierent 
across experimental groups. (E) Representative confocal images showing VGAT (red) and VGLUT1 (green) 
immunostaining. Scale bars: 2 µm. (F) e number of VGLUT1-positive glutamatergic synapses was fully 
rescued by exercise in the CA1 region of Ts65Dn hippocampus. Two-way ANOVA: genotype [F1,25 = 5.293, 
P = 0.030]; treatment [F1,25 = 5.239, P = 0.031]; genotype x treatment [F1,25 = 0.806, P = 0.378]. (G) e number 
of VGAT-positive GABAergic synapses was decreased by exercise in the CA1 region of both Ts65Dn and WT 
mice. Two-way ANOVA: genotype [F1,24 = 1.665, P = 0.209]; treatment [F1,24 = 15.933, P < 0.001]; genotype x 
treatment [F1,24 = 0.328, P = 0.572]. (H) Schematic representation of the hippocampal circuit and positioning 
of the stimulating and recording electrodes for LTP at Shaer collateral-CA1 synapses (CA3-CA1 LTP). (I) 
Average time course of the increase in the slope of fEPSP elicited in the CA1 Stratum Radiatum by stimulation 
www.nature.com/scientificreports/
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density of docked SVs in symmetric synapses was increased in Ts65Dn mice following exercise. However, these 
ultrastructural dierences were relatively small compared to the changes observed in the density of vGLUT1- and 
vGAT-positive puncta (Fig. 3E–G).
Since exercise completely restored synaptic decits in the CA1 region of trisomic animals, we next investi-
gated whether this observation translated to a rescue of the impairment in synaptic plasticity in Ts65Dn mice. 
We next evaluated LTP induction elicited by theta burst stimulation (TBS) at the Schaer collateral-CA1 path-
way (CA3-CA1 LTP, Fig. 3H) to address this question, and found that potentiation was signicantly lower in 
slices from sedentary Ts65Dn mice than in slices from WT littermates (Fig. 3I,J), similar to a previous report20. 
However, one month of physical exercise increased LTP induction at CA3-CA1 synapses in Ts65Dn mice (+28%) 
to levels indistinguishable from sedentary WT mice, whereas potentiation was unaltered in WT littermates 
(P = 0.21). us, physical exercise indeed eectively restores hippocampal synaptic plasticity in Ts65Dn mice in 
the CA3-CA1 circuit.
Aerobic exercise promoted BDNF expression. Aerobic exercise has been shown to increase the expres-
sion of brain-derived neurotrophic factor (BDNF) in the brain23–25,40,41,79, and exercise-induced upregulation of 
BDNF has been shown to be necessary for the enhancement of adult neurogenesis and spatial memory47,49,50. We 
therefore analyzed hippocampal BDNF expression in WT and Ts65Dn mice following the exercise paradigm. 
According to both ELISA and immunoblot quantication, the expression of the BDNF protein was indeed sim-
ilarly upregulated by exercise in WT and Ts65Dn mice (+50%) (Fig. 4A,B and Supplementary Fig. 4). BDNF 
mRNA transcripts are characterized by alternative exon usage at the 5′ untranslated region (UTR) and a common 
coding sequence (CDS). e expression of these alternative BDNF transcripts is controlled by multiple promoters 
that dierentially contribute to activity-dependent BDNF induction80–82. An analysis of the expression of dierent 
BDNF transcripts by real-time quantitative PCR (RT-qPCR) revealed that the exercise-induced increase in BDNF 
expression was mainly due to an enhancement of transcription from exons I, II and III in both WT and Ts65Dn 
mice (Fig. 4C), indicating that the molecular eectors of exercise that are recruited to enhance BDNF expression 
are substantially spared in trisomy.
???? ?????? ???????????????????????????????????????????????????????????????????????????-
???????? ?????? ????? e data reported above indicate a positive correlation between increased BDNF 
expression and memory enhancement in Ts65Dn mice. is link is also supported by a large body of evidence 
showing that many of the positive eects of exercise on the brain are mediated by BDNF40,41,44,47,49,50. erefore, 
we next investigated whether pharmacological induction of BDNF signaling in trisomic mice would be su-
cient to rescue the learning and memory impairment in trisomic animals. erefore, we took advantage of the 
recently developed BDNF-mimetic drug 7,8-dihydroxyavone (DHF), which crosses the brain-blood barrier 
upon oral administration83 and induces BDNF/TrkB signaling84–95. Previous reports have shown that acute DHF 
administration (5 mg/kg body weight) was able to promote TrkB phosphorylation in the brain; yet one study 
could not detect such eect84,86,92. erefore, we assessed the levels of TrkB phosphorylation aer acute DHF 
administration at the same dose. However, we could not detect any increase in the level of phosphorylated TrkB 
at Tyr817 (P-TrkBTyr817) in either the hippocampus or cortex of both WT and Ts65Dn mice 1 hour aer DHF 
administration (Fig. 5A,B). Nonetheless, other studies have reported activation of TrkB aer chronic DHF treat-
ment87,90–95. Accordingly, we found that chronic (4 weeks) administration of DHF signicantly increased the level 
of P-TrkBTyr817 (+26%) in the hippocampus of Ts65Dn mice (Fig. 5C). Notably, DHF-induced TrkB phosphoryl-
ation only showed a small increasing trend in the hippocampus of WT animals, but it did not reach statistical 
signicance (P = 0.091). Still, in the same group of WT and Ts65Dn animals, we could not detect a signicant 
increase of P-TrkBTyr817 in the cortex (Fig. 5D).
Next, we evaluated whether the chronic DHF treatment rescued hippocampal synaptic plasticity in Ts65Dn 
mice. e chronic DHF treatment largely phenocopied the eect of exercise on Ts65Dn mice by increasing 
CA3-CA1 LTP (+23%) to levels similar to vehicle-treated WT animals (Fig. 5E–G). Interestingly, the DHF treat-
ment also increased CA3-CA1 LTP in WT mice (+17%), highlighting the well-known involvement of TrkB sig-
naling in synaptic plasticity53–55.
Furthermore, we evaluated whether the rescue of hippocampal synaptic plasticity induced by the DHF treat-
ment was paralleled by a recovery of cognitive decits in trisomic animals. Chronic DHF treatment was well 
tolerated by mice and it did not induce changes in body weight gain or motor activity in either WT or Ts65Dn 
mice (Supplementary Fig. 5). e DHF treatment indeed rescued associative learning in DS mice in the CFC test, 
similar to the rescue observed with aerobic exercise (Fig. 6A,B), without inducing changes in non-associative 
freezing or altering sensitivity to the shock (Supplementary Fig. 6A). Moreover, spatial and discriminative memo-
ries were rescued by DHF in the OL and NOR tests (Fig. 6C,D), independent of object preference (Supplementary 
Fig. 6B,C). In contrast to aerobic exercise and the eects of the DHF treatment on T65Dn mice, DHF did not 
show a statistically signicant eect on WT mice. Based on these data, the DHF treatment rescues dierent forms 
of memory in Ts65Dn mice. ese data also point to the substantial specicity of the benecial eect of strategies 
promoting BDNF/TrkB signaling on DS mice.
of the Shaer collateral in hippocampal slices obtained from Ts65Dn and WT mice. (J) Quantication of 
CA3-CA1 LTP. Two-way ANOVA: genotype [F1,32 = 3.126, P = 0.087]; treatment [F1,32 = 7.269, P = 0.011]; 
genotype x treatment [F1,32 = 1.109, P = 0.300]. e number in parenthesis indicates the number of sample 
analyzed for each experimental group. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey post hoc test following two-
way ANOVA.
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BDNF expression is decreased in the brains of patients with DS. We next evaluated BDNF expres-
sion in the hippocampus of adult patients with DS (13–39 years old) prior to the development of an obvious 
Alzheimer’s neuropathology to obtain insights into the possible translational applicability of a BDNF-mimetic 
strategy as a treatment for cognitive impairment. Interestingly, BDNF expression was substantially reduced at 
both the mRNA and protein levels in the hippocampus of patients with DS compared to age/gender-matched 
normal controls (Fig. 7A,B), indicating that BDNF/TrkB signaling is likely defective in individuals with DS. As 
shown it the scatter plot representation of BDNF protein and mRNA expression, although the control and DS 
Figure 4. Physical exercise increased BDNF expression in the hippocampus of mice. (A) Top, schematic 
representation of the experimental protocol. Bottom, quantication of BDNF expression by ELISA 
immunoassay showed increased expression in the both WT and Ts65Dn running groups. Two-way ANOVA: 
genotype [F1,36 = 1.534, P = 0.224]; treatment [F1,36 = 12.862, P < 0.001]; genotype x treatment [F1,36 = 0.0224, 
P = 0.882]. (B) Top, representative immunoblot for BDNF in protein extracts from hippocampal samples 
collected from Ts65Dn and WT mice. Bottom, quantication of BDNF (expressed as percentage of sedentary 
WT) showed increased expression following exercise in the both WT and Ts65Dn mice. Actin was used an 
internal standard. Two-way ANOVA on ranked-transformed data: genotype [F1,44 = 0.000, P = 1.000]; treatment 
[F1,44 = 27.322, P < 0.001]; genotype x treatment [F1,44 = 0.547, P = 0.464]. e numbers in parenthesis indicates 
the number of samples for each experimental group. (C) Top, schematic representation of mouse Bdnf gene 
showing the exon organization of the 5′ and 3′ untranslated regions (UTR; white) and coding sequence (CDS; 
grey). Bottom, RT-qPCR analysis of mouse BDNF mRNA (expressed as percentage of sedentary WT) showed 
increased expression of transcripts from exons I, II, III and CDS in the hippocampus of exercised mice (n = 5-6 
for each experimental group). *P < 0.01, **P < 0.01, ***P < 0.001, Tukey post hoc test following two-way 
ANOVA. Full-length blots are presented in Supplementary Fig. 7.
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Figure 5. e BDNF-mimetic drug DHF stimulated TrkB signaling and rescued synaptic plasticity decits 
in the hippocampus of Ts65Dn mice. (A) Le, representative immunoblot for phosphorylated (Tyr817) or 
total TrkB (full-length and truncated isoforms: FL and T, respectively) and Actin in protein extracts from 
hippocampal samples collected from Ts65Dn and WT mice 1 hour aer acute administration of DHF (5 mg/
kg) or vehicle. Right, quantication of P-TrkBTyr817 (expressed as percentage of vehicle-treated WT) did not 
show dierences aer acute DHF administration. Two-way ANOVA on ranked-transformed data: genotype 
[F1,68 = 0.099, P = 0.753]; treatment [F1,68 = 1.730, P = 0.193]; genotype x treatment [F1,68 = 0.061, P = 0.806].  
(B) Le, representative immunoblot for phosphorylated or total TrkB and Actin in protein extracts from cortical 
samples collected from Ts65Dn and WT mice 1 hour aer acute administration of DHF or vehicle. Right, 
quantication of P-TrkBTyr817 did not show dierences aer acute DHF administration. Two-way ANOVA: 
genotype [F1,68 = 0.315, P = 0.576]; treatment [F1,68 = 0.019, P = 0.892]; genotype x treatment [F1,68 = 0.081, 
P = 0.776]. (C) Le, representative immunoblot for phosphorylated or total TrkB and Actin in protein extracts 
from hippocampal samples collected from Ts65Dn and WT mice chronically treated for 4 weeks with DHF or 
vehicle. Right, quantication of P-TrkBTyr817 showed a signicant increase in the hippocampus of DHF-treated 
Ts65Dn mice. Two-way ANOVA on ranked-transformed data: genotype [F1,41 = 2.383, P = 0.130]; treatment 
[F1,41 = 9.135, P = 0.004]; genotype x treatment [F1,41 = 0.302, P = 0.586]. (D) Le, representative immunoblot 
for phosphorylated or total TrkB and Actin in protein extracts from cortical samples collected from Ts65Dn 
and WT mice chronically treated for 4 weeks with DHF or vehicle. Right, quantication of P-TrkBTyr817 did 
not show dierences in the cortex of Ts65Dn and WT mice. Two-way ANOVA: genotype [F1,41 = 0.203, 
P = 0.665]; treatment [F1,41 = 1.570, P = 0.217]; genotype x treatment [F1,41 = 0.116, P = 0.686]. (E) Schematic 
representation of the experimental protocol and positioning of the stimulating and recording electrodes in 
hippocampal circuit for LTP at Shaer collateral-CA1 synapses. (F) Average time course of the increase in the 
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groups were clearly separated (Fig. 7C), the correlation between mRNA and protein levels in individual samples 
was relatively low (Pearson’s correlation coecients: −0.09 and −0.20 for controls and patients with DS, respec-
tively), indicating a possible dissociation between mRNA and protein levels in post-mortem human samples. 
However, as baseline BDNF expression is substantially downregulated at both the mRNA and protein levels in 
the hippocampus of patients with DS, the downstream TrkB signaling pathway is also likely to be compromised 
in patients with DS, thus highlighting the translational signicance of developing a BDNF-mimetic strategy for 
the treatment of the disease.
Discussion
Signicant cognitive dysfunction is nearly universal across the life span in persons with DS2,96–101. Although these 
cognitive diculties possibly arise from dysfunction of the hippocampal circuit2,4,102–105, we have only recently 
started to shed light on the neurobiological bases of these abnormalities through the use of mouse models of 
DS6,11,13–15,17–20,66,78,106,107. However, little progress has been achieved in translating these ndings into clinically 
eective treatments to date.
Here, the use of either aerobic exercise or a pharmacological treatment to promote BDNF signaling rescues 
cognitive symptoms in DS mice. Indeed, according to studies of human subjects and animal models, aerobic 
physical exercise induces BDNF expression, which, in turn, promotes structural and functional plasticity of neu-
rons, impacting on cognition and resistance to injury and diseases22–24.
Using light weight running apparatus with reduced friction that allowed mice to run considerable distances 
each day, aerobic exercise rescued excitatory synaptic decits in the hippocampal CA1 region of Ts65Dn mice by 
promoting functional synaptogenesis of glutamatergic terminals. is eect was paralleled by a substantial recov-
ery of synaptic plasticity in trisomic mice, as revealed by the rescue of defective LTP at Schaer collateral-CA1 
synapses. Accordingly, previous studies have indicated a prominent role for BDNF signaling in regulating synapse 
formation and LTP induction108.
According to several epidemiological studies involving children and adults, physical activity may improve 
cognitive performance and slow the progression of intellectual decline in aging humans24–28,32,34–37. In healthy 
humans, the levels of aerobic exercise correlate with sustained cerebral blood ow, improved memory perfor-
mances, increased circulating BDNF levels and increased hippocampal grey matter volume, likely due to the pro-
motion of adult neurogenesis in the DG29–33,39. Similarly, in rodents, exercise enhances hippocampus-dependent 
memory in dierent behavioral tasks38. e benecial eects of aerobic exercise on rodents have also been asso-
ciated with an upregulation of the BDNF/TrkB pathway23–25,40,41, increased neurogenesis in the hippocampal 
DG24,42–46, and the potentiation of synaptic plasticity47,48.
Here, we show an aerobic exercise-induced improvement in learning and memory in dierent behavioral 
tasks in DS mice. In particular, we observed a signicant improvement in dierent cognitive domains, including 
spatial memory (OL test), associative learning (CFC test) and episodic memory (NOR test). Previous studies 
evaluating the eect of exercise on learning and memory in DS mice have only reported limited ecacy. In the 
rst study, exercise only partially increased spatial acquisition in the Morris water maze (MWM) in relatively old 
male Ts65Dn mice (aged 10–12 months), but no improvement was detected during the MWM probe trial or in 
DG adult neurogenesis109. A second study did not observe a signicant impairment in sedentary female Ts65Dn 
mice compared to WT mice in the NOR test (but the authors used a dierent protocol than the protocol we 
used here). However, a slight increase in preference for the novel object was observed in Ts65Dn females when 
the mice were allowed access to running wheels beginning at weaning, but not when the exercise paradigm was 
administered in adulthood (starting from 7 to 17 months of age)110. Compared to our strong positive results, one 
main reason for the previously reported negative outcomes may reside in the low amount of running performed 
by aged Ts65Dn mice. Similarly, dierent behavioral tasks used for evaluations of cognitive performances and 
age- and gender-related dierences in the animals may also contributed to the dierence between our positive 
results and previous ndings.
Based on our results, the recovery of normal levels of cognitive function was accompanied by both structural 
and functional rescue of dierent decits in the trisomic brains. Consistent with previous studies highlighting 
the neurogenic eect of aerobic exercise46,48, voluntary wheel-running rescued adult neurogenesis in the hip-
pocampal DG of Ts65Dn mice in our study. In particular, wheel-running rescued impaired NPC proliferation 
and substantially increased the number of newly generated neurons in the DG of Ts65Dn mice. Importantly, the 
recovery of adult DG neurogenesis was paralleled by the functional integration of the newly generated neurons 
in the hippocampal circuit, since a bona de form of neurogenesis-dependent dentate LTP74–77, which is absent in 
Ts65Dn mice6, was in fact completely rescued by exercise. Consistent with previous studies46,48,68, wheel running 
increased hippocampal adult neurogenesis, DG-LTP and improved cognitive performances in WT mice; these 
eects where somewhat milder than in trisomic animals. Previous studies have reported a positive correlation 
between DG adult neurogenesis and cognitive performances in Ts65Dn mice6,111,112, highlighting the important 
role of this form of structural plasticity in the brain on neurophysiology and learning decits in trisomic animals.
We were also interested in identifying possible eects of exercise that were specic for trisomic animals and 
occurred in addition to DG adult neurogenesis. Accordingly, we report here for the rst time that the frequency 
slope of fEPSP elicited in the CA1 Stratum Radiatum by stimulation of the Shaer collateral in hippocampal 
slices obtained from Ts65Dn and WT mice. (G) Quantication of CA3-CA1 LTP. Two-way ANOVA: genotype 
[F1,24 = 8.459, P = 0.008]; treatment [F1,24 = 13.530, P = 0.001]; genotype x treatment [F1,24 = 0.0593, P = 0.810]. 
e number in parenthesis indicates the number of sample analyzed for each experimental group. *P < 0.05, 
Tukey post hoc test following two-way ANOVA. Full-length blots are presented in Supplementary Fig. 7.
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Figure 6. DHF treatment rescued memory decits in Ts65Dn mice. (A) Schematic representation of the 
experimental protocol. (B) Top, schematic representation of the contextual fear conditioning test. Le, 
one month of DHF treatment rescued contextual memory in Ts65Dn mice. Two-way ANOVA: genotype 
[F1,29 = 9.920, P = 0.004]; treatment [F1,29 = 15.754, P < 0.001]; genotype x treatment [F1,29 = 2.959, P = 0.096]. 
Right, both WT and Ts65Dn mice showed negligible freezing response when exposed to a new context. 
(C) Schematic representation of the object location (OL) test. Ts65Dn mice showed an absolute inability to 
discriminate the new object location aer a retention interval of 24 hours. DHF restored spatial memory in 
Ts65Dn mice. Two-way ANOVA: genotype [F1,52 = 26.522, P < 0.001]; treatment [F1,52 = 36.311, P < 0.001]; 
genotype x treatment [F1,52 = 49.978, P < 0.001]. (D) Schematic representation of the novel object recognition 
(NOR) test. One month of DHF treatment rescued novelty discrimination decits in Ts65Dn mice in the NOR 
test. Two-way ANOVA: genotype [F1,58 = 27.343; P < 0.001]; treatment [F1,58 = 32.390; P < 0.001]; genotype 
x treatment [F1,58 = 9.182; P = 0.004]. For all panels the number in parenthesis indicates the number of mice 
tested for each experimental group. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey post hoc test following two-way 
ANOVA.
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of mEPSCs recorded from CA1 pyramidal neurons (i.e., a non-neurogenic hippocampal region) was decreased 
in sedentary Ts65Dn mice compared to WT mice and was eectively restored by exercise. Notably, the density 
of glutamatergic synapses in hippocampal stratum radiatum was also reduced in sedentary Ts65Dn mice and 
rescued by exercise. ese results are consistent with previous immunohistochemical and electron microscopic 
studies showing a general decrease in the glutamatergic synapse density in the brains of Ts65Dn mice17,107,113–117 
along with a decrease in the mEPSC frequency in the hippocampal CA3 eld12,17. Although the eect of exercise 
on mEPSC frequency and glutamatergic synapse density appeared to be specic for trisomic brains in the pres-
ent study, exercise also signicantly reduced the density of GABAergic synapses and mIPSC frequency in both 
WT and Ts65Dn mice. We cannot exclude the possibility that the dierence in miniature postsynaptic current 
frequency may at least partially depend on changes in release probability, but the data presented here generally 
support the conclusion that variations in the number of glutamatergic and GABAergic synapses, rather than alter-
ations in the SV pools118,119, are linked to changes in both mEPSC and mIPSC frequencies. Consistent with our 
data, the density of GABAergic terminals in the brains of Ts65Dn mice was similar to WT mice in previous stud-
ies14,114,115,120,121. Furthermore, according to previous electrophysiological analyses, the mIPSC frequency, release 
probability at GABAergic synapses and GABAA-mediated transmission were unaected in the hippocampal CA1 
region of Ts65Dn mice13,78. However, possible sub-regional dierences may exist in the trisomic hippocampus, 
since other studies have observed an increased GABAergic synapse density in the inner molecular layer of the 
DG in Ts65Dn mice19,117. is nding was supported by the observation that the mIPSC frequency and evoked 
GABAergic transmission were increased in the DG of Ts65Dn mice11,14. e potential occurrence of sub-regional 
dierences in GABAergic innervation was also further highlighted by the observation that the mIPSC frequency 
was actually decreased in CA3 region of the Ts65Dn hippocampus12,17. Most importantly, Ts65Dn synaptic 
Figure 7. BDNF expression is reduced in the hippocampus DS patients. (A) RT-qPCR quantication of BDNF 
mRNA in the hippocampus of adult DS patients (open symbols: □ males; ○ females) in comparison to age/
sex matched non-trisomic controls (solid symbols: ■ males; ● females). Group averages (±SEM) are reported 
by lines. (B) Top, representative immunoblot for BDNF in protein extracts from human post-mortem whole 
hippocampus (gender is indicated above as squares for males and circles for females). Bottom, quantication 
of BDNF (expressed as percentage of controls) showed decreased expression in the hippocampus of adult DS 
patients in comparison to age/sex matched non-trisomic controls. Actin was used an internal standard. (C) 
Scatterplot representation of BDNF protein and mRNA expression for each individual samples. *P < 0.05, 
**P < 0.01 unpaired Student’s t-test. Full-length blots are presented in Supplementary Fig. 7.
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plasticity decits and cognitive impairments were suggested to arise from an imbalance between excitatory and 
inhibitory neurotransmission10–16. Based on our results, running-mediated recovery of the excitatory/inhibitor 
balance was paralleled by the selective rescue of LTP at CA3-CA1 synapses in exercised Ts65Dn mice. Consistent 
with previous studies, we did not observe signicant dierences in CA3-CA1-LTP between sedentary and run-
ning WT animals48, although exercise-induced changes in the GABAergic synapse density and mIPSC frequency 
(but not glutamatergic synapse density and mEPSC frequency) were similar to the changes observed in Ts65Dn 
littermates. erefore, the dual eects of physical exercise on both glutamatergic and GABAergic synapses in 
Ts65Dn mice likely contributes to the observed rescue of synaptic plasticity and cognitive performance.
Similar to aerobic exercise, environmental enrichment (EE) also represents a non-pharmacological method to 
promote brain plasticity, adult neurogenesis, BDNF expression and learning71,122,123. Indeed, previous studies on 
Ts65Dn mice exposed to EE have shown a substantial recovery of synaptic plasticity and cognitive performances, 
as well as increased BDNF expression and reduced neurotransmitter release from GABAergic terminals65,124. 
In this regard, enriched cages were also equipped with running wheels in these experiments; therefore, some of 
the benecial eects of EE may actually be ascribed to exercise. Interestingly, exercise has recently been shown 
to be a key factor that mediates increased BDNF expression, adult neurogenesis and enhanced cognitive perfor-
mances in response to EE68,79,125. Our results showing a reduced density of vGAT-positive puncta and mIPSC 
frequency in both WT and Ts65Dn mice aer running clearly suggest that exercise is an active component of 
the ability of the EE paradigm to modulate GABAergic functions. Interestingly, a study of Ts65Dn mice126 has 
suggested EE as a complementary adjuvant to pharmacological therapy with a polyphenolic green tea extract 
enriched in epigallocatechin-3-gallate (EGCG). Similarly, a recent clinical trial in patients with DS has introduced 
a computer-based cognitive training paradigm as an adjuvant to a green tea extract treatment127. Some encour-
aging, although limited, reports have indicated that aerobic exercise may be benecial in improving executive 
functions in patients with DS128–130. erefore, a controlled exercise paradigm may also be a valuable comple-
mentary intervention to pharmacological therapies for patients with DS. Nevertheless, in our experimental set-
ting, animals ran a considerable distance each day, and Ts65Dn mice ran an even greater distance. e increased 
activity observed in trisomic animals may likely be attributed to the reported hyperactivity of this mouse model5. 
However, from the clinical perspective, when considering the large distance travelled daily by Ts65Dn mice in 
our experiments, exercise may not be a practical medical intervention, since it strongly depends on motivation, 
which may be low in individuals with DS. us, a pharmacological approach, such as the one we propose here 
with DHF, mimicking the molecular changes induced by aerobic exercise may be an alternative and valuable 
therapeutic intervention.
BDNF has been postulated to act as a key mediator of exercise-associated cognitive improvement, enhanced 
neurogenesis and synaptic plasticity23,40,44,47,49,50,68. Similar to previous reports17,65–67,131,132, we conrm here that 
basal hippocampal BDNF levels are similar in young and middle-aged Ts65Dn mice compared to WT mice. 
However, BDNF expression was reduced in CA1 hippocampal neurons of elderly Ts65Dn mice133, indicating 
an age-related impairment in BDNF expression in trisomic mice. In this regard, some conicting results have 
been reported in the literature, since BDNF expression was reduced in the hippocampus of both young and 
middle-aged Ts65Dn mice134–137. As BDNF expression is inuenced by previous experience, gender, circadian 
rhythms or housing conditions138–142, dierences in these variables and the analysis method used may explain the 
reported discrepancies. Additionally, BDNF levels are reduced in the hippocampal DG (but not CA1) and frontal 
and visual cortices of Ts65Dn mice65,131, indicating that regional and sub-regional dierences in neurotrophin 
expression may occur in trisomic animals. On the other hand, BDNF expression was previously reported to be 
decreased in lymphoblastoid cell lines from individuals with DS143. Accordingly, we provide new evidence in 
this study showing that BDNF levels are substantially reduced in the hippocampus of young adults (mean age 23 
years) with DS, indicating that in contrast to animal models, the BDNF deciency occurs earlier in persons with 
DS. erefore, a BDNF-mimetic pharmacological intervention in individuals with DS may represent a strong 
therapeutic opportunity to rescue cognitive disabilities. Based on the known pivotal eect of BDNF signaling 
on cognition108,144, the observed increase in BDNF expression in Ts65Dn mice compared to the basal level may 
contribute to the benecial eect of running we observed in these mice. is result is consistent with other studies 
showing that the recovery of normal levels of cognitive function in Ts65Dn mice induced by dierent pharmaco-
logical interventions or EE are paralleled by increased BDNF expression17,65–67. Nevertheless, the BDNF level per 
se does not completely account for its downstream eects, since the neurotrophin is actively released at synapses 
and acts at both pre- and post-synaptic sites to regulate several processes through dierent intracellular signaling 
cascades108,145–147. Indeed, a recent study reported reduced surface binding of BDNF-conjugated Quantum dots 
(QD-BDNF) to Ts65Dn cortical synaptosomes compared to WT synaptosomes, together with a severely blunted 
response of the phosphorylation cascade downstream of TrkB upon BDNF application148, indicating that synaptic 
BDNF/TrkB signaling is likely altered in Ts65Dn mice.
Experiments assessing whether strategies that increase BDNF signaling compared to its basal level may be 
sucient to rescue the cognitive impairment in Ts65Dn mice are worthwhile in view of the possible translation 
to patients with DS. We therefore searched for a possible pharmacological treatment that mimicked the eect of 
physical exercise on potentiating BDNF signaling. We tested the eect of the BDNF-mimetic drug DHF that is 
orally active, crosses the brain-blood barrier, promotes TrkB phosphorylation and has been proven to be safe and 
well tolerated in rodents and primates84–95,149–151. Moreover, according to the results from in vivo pharmacokinetic 
studies in mice, DHF eciently penetrates the brain aer oral administration (50 mg/Kg), showing a brain to 
plasma concentration ratio of approximately 1:1 and an elimination half-life of about 2 hours83. However, an even 
longer half-life of 4–8 hours was measured in primate plasma aer oral administration (30 mg/Kg)150. Although 
DHF has been shown to activate TrkB in the brain aer acute administration85,86, we failed to detect any increase 
in TrkB phosphorylation in both WT and Ts65Dn mice aer a single dose. Such discrepancy may at least partially 
arise from dierence in the brain area analyzed in previous studies. However, our results are consistent with at 
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least one report showing increased TrkB phosphorylation only aer chronic, but not acute DHF treatment in the 
hippocampus of the Tg2576 mouse model of Alzheimer’s disease92. In keeping with this and other reports87,90–95, 
we found that chronic DHF treatment increased TrkB phosphorylation in the hippocampus of Ts65Dn mice. 
However, we could not nd a statistically signicant increase in TrkB phosphorylation in the hippocampus of 
their WT littermates. is result may indicate increased sensitivity to the drug in DS mice compared to WT, a 
hypothesis supported by previous observations showing increased TrkB phosphorylation in dierent mouse brain 
disease models, but not in the corresponding control animals88,92,94. Interestingly, the eect of DHF on TrkB phos-
phorylation was possibly specic for the hippocampus because the level of P-TrkBTyr817 was similar in the cortex 
of DHF- and vehicle-treated Ts65Dn mice. is indicates a possible dierent sensitivity to the drug in the cortex 
or the occurrence of compensatory and/or desensitization mechanisms.
Chronic oral administration of DHF rescued hippocampal synaptic plasticity and cognitive function in 
Ts65Dn mice. ese results largely mimicked the eect of exercise on Ts65Dn mice. However, the DHF treat-
ment enhanced hippocampal synaptic plasticity in WT to similar levels as trisomic animals, but it was unable 
to promote learning and memory in WT mice. erefore, in contrast to physical exercise, the DHF treatment 
appeared to specically enhance cognitive functions in trisomic animals, but not in WT littermates. Although we 
have not investigated this aspect, one possible explanation may be that overstimulation of this pathway in animals 
with intact BDNF signaling, as presumably found in WT mice, will have little eect on cognition. is possibility 
is corroborated by previous studies showing a positive eect of DHF on learning and memory in cognitively 
impaired animals, but not in the corresponding WT89,152. Alternatively, aerobic exercise may also recruit other 
signaling pathways relevant for memory in addition to BDNF in WT animals. However, in trisomic animals, 
where multiple neuronal and synaptic functions (possibly including neurotrophin signaling) are compromised, 
the stimulation of BDNF signaling may be sucient to rescue cognitive functions.
Moreover, the eect of DHF appeared to be consistent with previous studies showing that the administration 
of Neurotropin® (a drug previously proposed as analgesic for chronic pain) or ciliary neurotrophic factor (CNTF) 
peptide to increase hippocampal BDNF expression in Ts65Dn mice is associated improved spatial memory134,137. 
Regarding translational opportunities aorded by the present results, physical exercise may represent a valuable 
complementary therapy aimed at rescuing cognitive disabilities in patients with DS.
Although the care of associated medical issue has largely improved the overall health and life expectancy of 
individuals with DS, no eective pharmacological treatment is currently available to rescue cognitive decits. 
Here, we report pre-clinical data on this widely used mouse model of DS showing that either aerobic physical 
exercise and/or a DHF pharmacological treatment may represent a promising intervention for alleviating the 
learning and memory decits of patients with this syndrome.
Material and Methods
Animals and treatment. Ts65Dn colony5 was maintained by crossing Ts65Dn female to C57BL/6JEi x 
C3SnHeSnJ (B6EiC3) F1 males (Jackson Laboratories; Bar Harbor, USA). Animals were genotyped by PCR as 
previously described8. Ts65Dn male mice aged between 16 and 20 weeks were used for experiments and wild-
type (WT) littermates were used as controls throughout the study. Ts65Dn and WT littermates were randomly 
assigned to the running or sedentary groups. Running animals (two mice/cage) were housed for 4 weeks with 
two light weight and reduced friction running wheels (Med Associated). Sedentary mice were housed in standard 
cages without running wheels. For the assessment of the mean running distance, a cohort of WT and Ts65Dn 
mice was individually housed for 4 weeks with one running wheel equipped with a wireless revolution counting 
system (Med Associated). For neuron birth dating in neurogenesis experiments, mice were administrated with 
5-Bromo-2-Deoxyuridine (BrdU; 100 mg/kg body weight) through daily i.p. injections, for 6 consecutive days 
and perfused for immunohistochemistry 24 hours or 4 weeks aer the last injection6,153.
For neurogenesis assessment and quantication of synapses density (vGAT/vGLUT1, see below), we used 
mice aer concluding behavioral assessment in the NOR or OL test. Due to the more stressful nature of the CFC 
test, none of the mice subjected to this test was later used for other experiments. Detailed list of mice used in the 
study is provided in Supplementary Table 4.
For 7,8-dihydroxyavone (DHF) treatment, the drug was administered through the drinking water, as previ-
ously described149. DHF (TCI Europe) stock solution was prepared at 100 mg/ml in dimethylsolfoxide (DMSO) 
and stored in aliquots at −20 °C. is stock solution was diluted at 80 mg/L in drinking water containing 0.2% 
(w/v) sucrose149. e DHF drinking solution was replaced every 2-3 days and water intake monitored throughout 
the experiments. e average water intake during the four weeks of treatment was used to calculate the aver-
age DHF dose received by mice, which was estimated in 22.16 ± 1.64 mg/Day/Kg body weight. Vehicle-treated 
mice received drinking water containing 0.08% (v/v) DMSO and 0.2% (w/v) sucrose. Chronic DHF treatment 
appeared to be well tolerated by mice. Only 1 out of 85 vehicle-treated mice and 1 out of 97 DHF-treated mice 
died during the study.
For acute drug administration, mice were treated as previously described84,86,92 with DHF (i.p., 5 mg/Kg body 
weight) or the corresponding vehicle (10% DMSO in saline) and sacriced 1 hour later. To minimize possible cir-
cadian eects on gene expression, collection of all samples for biochemical analysis was performed between 9.00 
and 12.00 AM. Brains were rapidly dissected in ice-cold PBS and immediately snap-frozen.
???????????????????? Behavioral tests were performed on each animal during the 4th week of treatment as 
previously described6,15. Animal behavior was video-recorded throughout the experimental sessions, and sub-
sequently analyzed by a trained operator blind to the experimental groups. WT and Ts65Dn mice were always 
evaluated in parallel and with the same time schedule. In order to avoid any confounding eect, tests were admin-
istrated only once to individual mice and, various cohorts of mice were used for dierent behavioral testing. ree 
days before starting the behavioral experiments mice where handled once a day for 5 min each.
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Object location test (OL). is test measures spatial memory by evaluating the ability of mice to recognize the 
new location of familiar object with respect spatial external cues. e test was conducted in a grey acrylic arena 
(44 × 44 cm) equipped with a digital video recording system. e test was conducted during 3 consecutive days. 
On the rst day mice were rst habituated to the empty arena for 15 minutes. e next day the mice were exposed 
to 2 identical objects for 15 minutes (acquisition session). Object preference was evaluated during this session. On 
the third day (trial session) one the object was moved to a novel location, and the mice were allowed to explore 
the objects for 15 minutes. e object and the arena were cleaned with 70% ethanol aer each trial. Exploratory 
behavior of the objects was dened as direct contact with the object by the animal mouth, nose or paws, or if 
the animal’s nose was within 1 cm of an object (sning); any indirect or accidental contact with the objects was 
not included in the scoring. A discrimination index was calculated as the percentage of time spent investigating 
the object in the new location minus the percentage of time spent investigating the object in the old location: 
Discrimination Index = (New OL Exploration Time/Total Exploration Time * 100) − (Old OL exploration time/
Total Exploration Time * 100).
Novel object location test (NOR). is test measures the preference of mice for a novel object versus previously 
encountered familiar objects. e test was conducted in a grey acrylic arenas (44 × 44 cm) equipped with a digital 
video recording system as above. e NOR test was conducted during 3 consecutive days, similarly to the OL test. 
On the rst day the mice were habituated to the apparatus by freely exploring the empty arena for 15 minutes. 
e next day (acquisition session), three dierent objects were placed into the arena and the mice were allowed 
to explore for 15 minutes. Object preference was evaluated during these sessions. e objects used during the 
test were dierent in shape, color, size and material. On the third day (trial session) one the object used during 
the acquisition session was replaced by a novel object and the mice were allowed to freely explore the objects 
for 15 minutes. e objects and the arena were cleaned with 70% ethanol between trials. Exploratory behavior 
of the object was dened as direct contact with the object by the animal mouth, nose or paws, or if the animal’s 
nose was within 1 cm of an object (sning); any indirect or accidental contact with the objects was not included 
in the scoring. A discrimination index was calculated as the dierence between the percentages of time spent 
investigating the novel object and the time spent investigating the familiar objects: Discrimination Index = (New 
Object Exploration Time/Total Exploration Time * 100) − (Familiar Object Exploration Time/Total Exploration 
Time * 100).
Motor activity. e distance traveled by mice in the empty arena during the habituation sessions of the OL and 
NOR tests was measured with ANY-maze tracking soware (Stoelting).
Contextual fear conditioning test (CFC). e fear conditioning system (TSE) consisted of a transparent acrylic 
conditioning chamber (20 × 10 cm) equipped with a stainless-steel grid oor and a digital video recording system. 
Mice were held outside the experimental room in their home cages prior to testing and individually transported 
to the conditioning apparatus in standard cages. e mice were placed in the conditioning chamber and 3 min-
utes later, received one electric shock (2 s, 0.75 mA constant electric current) through the oor grid. Mice were 
removed 15 s follow the shock. 24 hours later, the mice were placed in the same chamber for 3 minutes (context 
test) and aer 2 hours moved to a new context (black chamber with plastic gray oor and vanilla odor). e cham-
ber was cleaned with 70% ethanol aer each trial. e freezing behavior was scored by a trained operator blinded 
to the experimental groups.
e NOR and OL test were performed in dim light illumination (12–14 Lux), while CFC was conducted with 
standard illumination (80 Lux). In behavioral experiments, we adopted the following exclusion criteria inde-
pendently of genotype or treatment (before blind code break). In the CFC test, we excluded mice showing very 
high non-associative freezing in the new context: more than 30 seconds freezing during the 3 minutes test (5 
out of 86 mice). In the OL and NOR test, we excluded animals showing very low explorative behavior: less than 
10 seconds of direct objects exploration during the 15 minutes test (2 out of 113 mice for OL test and 4 out of 131 
mice for NOR test).
Immunohistochemistry. Animals were deeply anesthetized and transcardially perfused with 4% paraform-
aldehyde in 100 mM phosphate buer (PB), pH 7.4. Brains were collected, post-xed for 24 h in the same xative 
solution, cryo-preserved in 30% sucrose in PB and stored at −80 °C until use. Immunohistochemistry was per-
formed on 30-µm coronal sections, with the following primary antibodies: rat anti-BrdU (clone BU1/75[ICR1], 
Abcam, catalog n°: ab6326; 1:200); rabbit anti-DCX (Abcam, catalog n°: ab18723; 1:1000); mouse anti-NeuN 
(clone A60, Millipore, catalog n°: MAB377; 1:250); rabbit anti-GFAP (Abcam, catalog n°: ab16997; 1:100); rab-
bit anti-vGAT (SYSY, catalog n°: 131-013; 1:700); guinea pig anti-vGLUT1 (SYSY, catalog n°: 135–304; 1:2500). 
Fluorophore conjugated (Alexa Fluor 488, Alexa Fluor 568, Alexa Fluor 647), goat secondary antibodies (1:1000; 
Invitrogen) were used for detection. e sections were counterstained with the nuclear dye Hoechst-33342 
(Sigma-Aldrich). For BrdU immunohistochemistry, sections were pretreated with 2 N HCl as previously 
described6.
For the assessment of dentate adult neurogenesis, stereological cell counting was performed in serial coro-
nal sections (180 µm apart) covering the complete rostro-caudal extension of the dentate gyrus as previously 
described6. Fluorescence images were captured with a Nikon A1 confocal scanning microscope equipped with 
a 40X air objective and a motorized stage. For each section, confocal z-stack images (1 µm z-step size) cover-
ing the complete dentate gyrus were acquired and DG reconstructed with NIS Element AR soware (Nikon). 
Immunolabeled cells in the granular cell layer (GCL) and the subgranular zone (SGZ, dened as a 10 µm region 
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below the GCL) were counted on the reconstructed images by an operator blind to the experimental groups 
according to the optical dissector principle153.
For quantitative analyses of vGAT- and vGLUT1-positive puncta density, measurements were performed 
on images acquired with a SP5 confocal scanning microscope (Leica Microsystems), equipped with a 63X 
oil-immersion objective. Puncta density was evaluated on serial coronal sections (180 µm apart) covering the 
complete rostro-caudal extension of the hippocampus. Puncta immunostained for vGAT and vGLUT1 were auto-
matically quantied in random elds of the CA1 stratum Radiatum on single-plain optical section images using 
the particle analysis plugin available in ImageJ soware (http://imagej.nih.gov/ij/).
Electron Microscopy. Coronal brain slices (30 µm thickness) were post-xed by immersion in 2% gluta-
raldehyde in 0,1 M sodium Cacodylate buer (NaCacodylate, pH 7.4). Following aldehyde xation, slices were 
rinsed in 0,1 M NaCacodylate buer and further treated for 1 hours with 1% OsO4 in 1.5% K4Fe(CN)6 in 0.1 M 
NaCacodylate at room temperature, en bloc stained with 1% uranyl acetate for 45 minutes, dehydrated through 
a series of graded ethanol solutions, washed in propylene oxide and at embedded in epoxy resin (Epon 812, 
TAAB) between two Aclar sheets. Aer 48 hours of polymerization at 60 °C, a small region corresponding to 
the hippocampal CA1 was excised from the blocks of resin and cut with an EM UC6 ultramicrotome (Leica 
Microsystem). Semi-thin section (0,5 µm thickness) was taken from each brain slice, stained with 1% of toluidine 
blue and analyzed at low magnication to identify the central region of CA1 stratum Radiatum. Ultrathin sections 
(70 nm thickness) were collected on 200 mesh copper grids and observed with a JEM-1011 microscope (Jeol) 
operating at 100 kV and equipped with an ORIUS SC1000 CCD camera (Gatan).
Symmetric (GABAergic) and asymmetric (glutamatergic) synapses were morphologically identied based 
on the shape of the presynaptic bouton and presence of thick and electron-dense post-synaptic density typical of 
glutamatergic terminals154,155. Synaptic bouton areas, length of the active zone (AZ), total and docked SV densi-
ties were calculated using ImageJ soware. Total SV density was calculated on the total area of each presynaptic 
bouton. AZ was morphologically identied as the opposition region between pre- and post- synaptic structures 
with docked SV. Docked SV density was calculated on the length of the active zone of each presynaptic bouton. 
Only synapses with at least one docked synaptic vesicles were analyzed.
Biochemistry. Samples were lysed in ice-cold RIPA buer (1% NP40, 0.5% Deoxycholic acid, 0.1% SDS, 
150 mM NaCl, 1 mM EDTA, 50 mM Tris, pH 7.4) containing 1 mM PMSF, 10 mM NaF, 2 mM sodium ortho-
vanadate and 1% (v/v) protease and phosphatase inhibitor cocktails (Sigma). Samples were claried through 
centrifugation at 20,000 × g at 4 °C, and the protein concentration was determined using the BCA kit (Pierce). 
For immunoblot analysis, equal amounts of proteins were run on 4–12% Bis-Tris NuPAGE (Life Technologies) or 
Criterion-XT (Bio-Rad) gels and transferred overnight at 4 °C onto nitrocellulose membranes (GE Healthcare). 
Membranes were probed with rabbit anti-BDNF (Santa Cruz Biotechnology, catalog n°: sc-546; 1:500)66, rabbit 
anti-phospho-TrkBTyr817 (Abcam, catalog n°: ab81288; 1:20000), rabbit anti-TrkB (Millipore, catalog n°: 07-225; 
1:2000), and rabbit anti-Actin (Sigma, catalog n°: A2066; 1:10000), followed by HRP-conjugated goat second-
ary antibodies (ermo Scientic) or uorophore-conjugated (Cy3 or Cy5) goat secondary antibodies (GE 
Healthcare). Chemiluminescence signals were revealed with the SuperSignal West Pico substrate (Pierce) and 
digitally acquired on a LAS 4000 Mini imaging system (GE Healthcare). Fluorescent signals were acquired with 
Typhoon uorescent scanner (GE Healthcare). Band intensities were quantied using ImageQuant soware (GE 
Healthcare). For the determination of phospho-TrkB levels in brain lysates, membranes were rst probed with 
the phospho-specic antibody, stripped and re-probed with a second antibody for total TrkB. e specicity of 
anti-BDNF antibody was veried by immunoblot analysis of recombinant BDNF (PeproTech) (Supplementary 
Fig. 4).
BDNF quantication by “sandwich” enzyme-linked immunosorbent assay (ELISA) was performed with 
BDNF Emax ImmunoAssay System (Promega) on 50 µg of hippocampal protein extracts (as above) according to 
the manufacturer’s instructions. Absorbance at 450 nm was measured with a Victor3 plate reader (PerkinElmer).
????? ? ?? ??????????????????????????? RT-qPCR was performed as previously described15,156. RNA 
was extracted with QIAzol reagent and puried on RNeasy spin columns (Qiagen), which includes an in-column 
RNAse-free DNAse digestion for the removal of contaminating genomic DNA. RNA samples were quantied 
at 260 nm with a ND1000 Nanodrop spectrophotometer (ermo Scientic). RNA purity was also determined 
by absorbance at 280 and 230 nm. Reverse transcription was performed according to the manufacturer’s recom-
mendations on 1 µg of RNA with QuantiTect Reverse Transcription Kit (Qiagen). SYBR green RT-qPCR was 
performed in triplicate with 10 ng of template cDNA using QuantiTect master mix (Qiagen) on a 7900-HT Fast 
Real-time System (Applied Biosystem), using the following universal conditions: 5 min at 95 °C, 40 cycles of 
denaturation at 95 °C for 15 sec, and annealing/extension at 60 °C for 30 sec. Product specicity and occurrence 
of primer dimers were veried by melting curve analysis. Primers were designed with Beacon Designer soware 
(Premier Bioso) in order to avoid template secondary structure and signicant cross homologies regions with 
other gene by BLAST search. For each target gene, primers were designed to target specic transcript variants 
annotated in RefSeq database (http://www.ncbi.nlm.nih.gov/refseq). In each experiment no-template controls 
(NTC) and RT-minus controls were run in parallel to the experimental samples. PCR reaction eciency for each 
primer pair was calculated by the standard curve method with serial dilution of cDNA. PCR eciency calculated 
for each primer set was used for subsequent analysis. All experimental samples were detected within the linear 
range of the assay. Gene expression data were normalized by the multiple internal control gene method157. To 
determine an accurate normalization factor for data analysis the expression stability of dierent control genes was 
evaluated with GeNorm algorithm157 available in qBasePlus soware (Biogazelle). e tested control genes were: 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), PPIA (peptidylprolyl isomerase A) and ACTB (β-actin). 
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Based on the relative expression stability of the control genes calculated by GeNorm analysis, expression data for 
the dierent samples were normalized with GAPDH and PPIA. However we noted that expression stability of the 
control genes was generally similar, therefore comparable expression results were obtained also by normalization 
with the other control genes. SYBR green primer sequences are reported in Supplementary Table 1. Calibration 
curves parameters, PCR reaction eciency and amplicon information are listed in Supplementary Table 2.
Human Brain Samples. Hippocampal samples from adult human Down syndrome patients and age/
sex-matched non-trisomic controls were obtained from the Brain and Tissue Bank for Developmental Disorders 
at the University of Maryland, Baltimore (MD). Samples information are described in Supplementary Table 3 
and were previously reported15. Samples were cryo-pulverized in dry ice (−78 °C) with a stainless steel mortar. 
Aliquots of pulverized tissue were used for protein and RNA extraction.
Electrophysiology. Field recordings. For CA3-CA1 LTP mice were anesthetized with isourane and tran-
scardially perfused with an ice-cold ACSF solution with the following composition (in mM): 120 NaCl, 3.5 KCl, 
1.25 NaH2PO4, 1.3 MgSO4, 2.5 CaCl2, 26 NaHCO3 and 10 glucose (pH 7.4), oxygenated with 95% O2 and 5% 
CO2
15,20. e animal was sacriced, and the brain was removed and immersed in ice-cold ACSF. Sagittal slices 
(400 µm) were prepared with a VT1000S vibratome (Leica Microsystems) and incubated at 35 °C for 20 minutes 
in oxygenated ACSF. Aer 2 h recovery at room temperature, slices were transferred to a recording chamber 
and perfused with ACSF (35 °C, 1.7 mL/min). Electrical stimulation (100 µs duration) of Shaer collateral was 
achieved by a bipolar tungsten stimulating electrode (WPI, USA) placed in the stratum radiatum. Field excitatory 
post-synaptic potentials (fEPSPs) in CA1 stratum radiatum were recorded by a micropipette (1–3 MΩ) lled with 
ACSF. Baseline responses were obtained every 30 s with a stimulation intensity that yielded a half-maximal slope 
(mV/ms) response. Aer achievement of a 10 min stable baseline, a theta-burst stimulation (TBS) was delivered. 
e protocol of TBS stimulation consisted of 5 bursts at 5 Hz, each burst consisted of 4 pulses at 100 Hz15,20. Data, 
ltered at 0.1 Hz and 600 Hz and sampled at 25 kHz were acquired with a patch-clamp amplier (Multiclamp 
700B, Molecular Devices), and analyzed using pClamp 10.2 soware (Molecular Devices).
For DG LTP mice were anesthetized with isourane and transcardially perfused with an ice-cold ACSF solu-
tion containing (in mM): 119 NaCl, 2.5 KCl, 1.3 MgSO4, 1 NaH2PO4, 26 NaHCO3, 2.5 CaCl2, and 10 glucose (pH 
7.4), oxygenated with 95% O2 and 5% CO2
6. e animal was sacriced, and the brain was removed and immersed 
in ice-cold ACSF. Transverse hippocampal slices (400 µm) were prepared using a Microm HM 650 V vibratome 
equipped with Microm CU 65 cooling unit (ermo Scientic) and incubated at 32 °C for 30 minutes in oxygen-
ated ACSF. Slice were then transferred into a holding chamber containing oxygenated ACSF and incubated for 
at least 90 minutes at room temperature before recording. e slices were transferred into a recording chamber 
and continuously perfused with oxygenated ACSF (2 ml/min) at 31 °C ± 1 °C. Aerent bers on the media per-
forant path (MPP) were stimulated using a bipolar tungsten stimulating electrode (WPI, USA), and fEPSPs were 
recorded using glass capillary electrodes (4–5 MΩ) lled with ACSF positioned in the medial molecular layer of 
the upper blade of the DG. Baseline recordings were conducted with a frequency of 1 test stimulus every 30 sec-
onds. Only slices showing fEPSPs of 1 mV in amplitude or higher were selected for experiments. LTP was induced 
through a tetanic stimulation that consisted of four 100-Hz trains of 0.5 seconds each repeated every 30 seconds. 
Aer induction, the responses were recorded every 30 seconds for at least 60 minutes. e data were 0.1–1000 Hz 
band-pass ltered and amplied using a DAM 80 amplier (WPI), digitized at a sampling rate of 25 kHz using a 
Digidata 1440 A (Molecular Devices) running with Clampex soware (Molecular Devices). e Clampt soware 
(Molecular Devices) was used for data analysis.
Patch-clamp recordings. Whole-cell patch-clamp recordings from CA1 pyramidal neurons were performed 
using Multiclamp 700B/Digidata1440A system (Molecular Devices, Sunnyvale CA, USA) and an upright 
Olympus BX51WI microscope (Olympus) equipped with Nomarski optics. Aer anesthetization with isourane, 
transverse hippocampal slices (400 µm) were cut using a Microm HM 650 V microtome equipped with Microm 
CU 65 cooling unit (ermo Fisher Scientic). Slices were cut at 2 °C in a solution containing (in mM): 87 NaCl, 
25 NaHCO3, 2.5 KCl, 0.5 CaCl2, 7 MgCl2, 25 glucose, and 75 sucrose saturated with 95% O2 and 5% CO2. Aer 
cutting the slices were le to recover for 1 hour at 35 °C and for another 2 hours at room temperature in recording 
solution. Experiments were performed at 22–24 °C. e extracellular solution used for recordings contained (in 
mM): 125 NaCl, 25 NaHCO3, 25 glucose, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, and 1 MgCl2 (bubbled with 95% O2-
5% CO2). All experiments were performed at a holding potential Vh = −70 mV in the presence of 0.3 µM TTX 
(Tocris Bioscience). Miniature excitatory postsynaptic currents (mEPSP) were recorded with an internal solution 
containing (in mM): 126 K gluconate, 4 NaCl, 1 MgSO4, 0.02 CaCl2, 0.1 BAPTA, 15 Glucose, 5 HEPES, 3 ATP, 
0.1 GTP (pH 7.3) in the presence of 30 µM bicuculline and 5 µM CGP55845 (Tocris Bioscience) to block GABAA 
and GABAB receptors, respectively. Miniature inhibitory postsynaptic currents (mIPSP) were recorded with a 
high-chloride intracellular solution containing (in mM): 126 KCl, 4 NaCl, 1 MgSO4, 0.02 CaCl2, 0.1 BAPTA, 
15 Glucose, 5 HEPES, 3 ATP and 0.1 GTP (pH 7.3) in the presence of 50 µM D-AP5 and 10 µM CNQX (Tocris 
Bioscience) to block NMDA and non-NMDA receptors, respectively. Somatic access resistance was monitored 
continuously, and cells with access resistance larger than 15 MΩ and/or a holding current larger than −200 pA 
were excluded. All patch-clamp data were acquired with Clampex 10.2 and analyzed oine with Clampt 10.2 
(pClamp, Molecular Devices) and MiniAnalysis (Synaptoso).
Statistical analysis. e results are presented as the means ± SEM. e statistical analysis was performed 
using SigmaPlot (Systat) and GraphPad (Prism) soware. Where appropriate, the statistical signicance was 
assessed using the following parametric test: two-tailed unpaired t-test, two-way ANOVA or two-way repeated 
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measure ANOVA followed by all pairwise Turkey’s post hoc test. In case normal distribution or equal variance 
assumptions were not valid, statistical signicance was evaluated using Mann-Whitney test (non-parametric) or 
by two-way ANOVA on ranked transformed data. P values < 0.05 were considered signicant.
????????????????? ???????????? A veterinarian was employed to monitor health and comfort of the animals. 
Mice were housed in a temperature-controlled room with a 12:12 hour dark/light cycle with ad libitum access 
to water and food. All animal experiments were performed in accordance with the guidelines established by the 
European Community Council Directive 2010/63/EU of September 22nd, 2010 and were approved by the Italian 
Ministry of Health (authorization n°: 216/2012-B and 658/2016-PR).
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Supplementary text and figures: 
 
 
 
 
 Supplementary Figure 1. Physical exercise had no effect on general motor activity. (A) Distance traveled in 
the empty arena was not different across genotype and treatments. Two-way ANOVA on ranked 
transformed data: genotype [F1,116 = 4.460, P = 0.037], treatment [F1,116 = 0.038, P = 0.845], genotype x 
treatment [F1,116 = 0.015, P = 0.901]. Tukey post hoc test following two-way ANOVA did not reach 
statistical significance for any experimental group. Number in parenthesis indicates the number of mice 
tested for each experimental group.  
 
 Supplementary Figure 2. (A) Physical exercise had no effect on the freezing time before (left) or 
immediately after (right) the electric foot shock during the conditioning session in both Ts65Dn and WT 
mice. Pre-shock two-way ANOVA on ranked transformed data: genotype [F1,45=1.964, P=0.168]; treatment 
[F1,45=0.0661, P=0.798]; genotype x treatment [F1,45=0.00002, P=0.996]. Post-shock two-way ANOVA: 
genotype [F1,45=0.171, P=0.681]; treatment [F1,45= 0.169, P=0.683]; genotype x treatment [F1,45=0.194, 
P=0.661]. (B) Left: in the OL test the total exploration time during the acquisition phase was not 
significantly different across genotype and treatment. Two-way ANOVA: genotype [F1,51=5.017, P=0.029]; 
treatment [F1,51=0.641, P=0.427]; genotype x treatment [F1,51=0.0223, P=0.882]. Center: the total 
exploration time during the trial phase was slightly increased in sedentary Ts65Dn mice compared to WT, 
however no significant difference was observed in Ts65Dn running mice compared to WT. Two-way 
ANOVA: genotype [F1,51=9.164, P=0.004]; treatment [F1,51=2.453, P=0.123]; genotype x treatment 
[F1,51=0.914, P=0.349]. **P<0.01, Tukey post hoc test. Right: the percentage of time spent exploring the 
two objects during the acquisition phase was not statistically different across the experimental groups. Two-
way ANOVA: genotype [F1,102<0.0001, P=1.000]; treatment [F1,102=1.331, P=0.268]; genotype x treatment 
[F1,102=0.4014, P=0.753]. (C) Left: in the NOR test the total exploration time during the acquisition phases 
was not significantly different across genotype and treatment. Two-way ANOVA on ranked transformed 
data: genotype [F1,61=0.585; P=0.447]; treatment [F1,61=0.548; P=0.462]; genotype x treatment 
[F1,61=0.0997; P=0.753]. Center: the total exploration time during the trial phase was not significantly 
different across genotype and treatment. Two-way ANOVA on ranked transformed data: genotype 
[F1,61=0.0226; P=0.881]; treatment [F1,61=1.892; P=0.174]; genotype x treatment [F1,61=2.047; P=0.158]. 
Right: the percentage of time spent exploring the three objects during the acquisition phase was not 
statistically different across the experimental groups. Two-way ANOVA: genotype [F1,187=0.231; P=0.645]; 
treatment [F1,187=0.718; P=0.629]; genotype x treatment [F1,187=0.895; P=0.521]. Number in parenthesis 
indicates the number of mice tested for each experimental group.  
 
 
Supplementary Figure 3. Synaptic ultrastructural morphometric analysis in the hippocampal CA1 region. 
(A) Representative TEM images showing asymmetric (glutamatergic) synapses. (B) Mean asymmetric 
synaptic bouton area was not significantly different across genotype and treatment. Two-way ANOVA: 
genotype [F1,15=0.108, P=0.748]; treatment [F1,15=3.218, P=0.098]; genotype x treatment [F1,15=0.097, 
P=0.761]. (C) Total synaptic vesicles (SV) density in asymmetric synapses was not significantly different 
across genotype and treatment. Two-way ANOVA: genotype [F1,15=1.078, P=0.320]; treatment 
[F1,15=1.333, P=0.271]; genotype x treatment [F1,15=0.045, P=0.836]. (D) The density of docked SV in 
asymmetric synapses was not significantly different across genotype and treatment. Two-way ANOVA: 
genotype [F1,15=1.797, P=0.205]; treatment [F1,15<0.0001, P=0.997]; genotype x treatment [F1,15= 0.779, 
P=0.395]. (E) In asymmetric synapses the length of the active zone was increased by exercise in both WT 
and Ts65Dn mice. Two-way ANOVA: genotype [F1,15=1.889, P=0.194]; treatment [F1,15=16.940, P=0.001]; 
genotype x treatment [F1,15=0.0745, P=0.790]. (F) Representative TEM images showing symmetric 
(GABAergic) synapses. (G) Mean symmetric synaptic bouton area was not significantly different across 
genotype and treatment. Two-way ANOVA: genotype [F1,15=0.0952, P=0.763]; treatment [F1,15=0.679, 
P=0.426]; genotype x treatment [F1,15=0.353, P=0.564]. (H) Total SV density in symmetric synapses was 
not significantly different across genotype and treatment. Two-way ANOVA: genotype [F1,15=1.379, 
P=0.263]; treatment [F1,15=0.124, P=0.731]; genotype x treatment [F1,15=1.145, P=0.306]. (I) The density of 
docked SV in symmetric synapses was reduced in sedentary Ts65Dn mice and significantly restored by 
exercise. Two-way ANOVA: genotype [F1,15=6.265, P=0.028]; treatment [F1,15=1.633, P=0.225]; genotype 
x treatment [F1,15=4.922, P=0.047]. (J) In symmetric synapses the length of the active zone was not 
significantly different across genotype and treatment. Two-way ANOVA: genotype [F1,15=2.777, P=0.121]; 
treatment [F1,15=6.939, P=0.022]; genotype x treatment [F1,15=0.0233, P=0.881]. *P<0.05, **P<0.01, Tukey 
post hoc test following two-way ANOVA. Number in parenthesis indicates the number of mice tested for 
each experimental group.  
 
 
 
 
  
 
Supplementary Figure 4. Specificity of the anti-BDNF antibody used for western blot analysis. 
Representative immunoblot with anti-BDNF antibody on hippocampal protein extracts or recombinant 
BDNF (rBDNF). Actin was used as loading control and is absent in rBDNF line. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 5. DHF treatment had no effect on body weight gain and general motor activity. (A) 
Mice body weight was measured at the beginning and at the end (4 weeks later) of chronic DHF or vehicle 
treatment. As previously reported (Costa, et al. 2010), mean body weight was greater in WT than in Ts65Dn 
mice (P<0.001). All groups of mice showed comparable and significant weight gain (P<0.001 for all 
groups) during the 4-week treatment period independently of genotype. Two-way repeated measure 
ANOVA on ranked-transformed data: genotype [F3,114 = 8.509, P < 0.001], time-point [F1,114 = 59.318, P < 
0.001], genotype x time-point [F3,114 = 0.407, P = 0.748]. ***P<0.001, Tukey post hoc test. (B) Motor 
activity was evaluated by measuring the distance traveled in the empty arena by mice after chronic DHF or 
vehicle treatment. Distance traveled was not different across genotype and treatments. Two-way ANOVA: 
genotype [F1,114 = 4.058, P = 0.046], treatment [F1,114 = 0.039, P = 0.843], genotype x treatment [F1,114 = 
0.313, P = 0.577]. Tukey post hoc test following two-way ANOVA did not reach statistical significance for 
any experimental group. Number in parenthesis indicates the number of mice tested for each experimental 
group.   
 
  
Supplementary Figure 6. (A) DHF treatment had no effect on the freezing time before (left) or immediately 
after (right) the electric foot shock during the conditioning session in both Ts65Dn and WT mice. Pre-shock 
two-way ANOVA: genotype [F1,29=1.357, P=0.254]; treatment [F1,29=0.505, P=0.483]; genotype x 
treatment [F1,29=1.665, P=0.207]. Post-shock two-way ANOVA: genotype [F1,29=0.576, P=0.454]; 
treatment [F1,29=0.140, P=0.711]; genotype x treatment [F1,29=2.394, P=0.133]. (B) Left: in the OL the total 
exploration time during the acquisition phase was not significantly different across genotype and treatment. 
Two-way ANOVA: genotype [F1,52=0.0084, P=0.927]; treatment [F1,52=0.0005, P=0.981]; genotype x 
treatment [F1,52=0.0803, P=0.778]. Center: the total exploration time during the trial phase was not 
significant different across genotype and treatment. Two-way ANOVA: genotype [F1,52=0.215, P=0.645]; 
treatment [F1,52=3.764, P=0.058]; genotype x treatment [F1,52=0.972, P=0.329]. Right: the percentage of 
time spent exploring the two objects during the acquisition phase was not statistically different across the 
experimental groups. Two-way ANOVA: genotype [F1,102<0.0001, P=1.000]; treatment [F1,102=1.108, 
P=0.349]; genotype x treatment [F1,102=2.680, P=0.051]. Number in parenthesis indicates the number of 
mice tested for each group experimental. (C) Left: in the NOR test the total exploration time during the 
acquisition was not significantly different across genotype and treatment. Two-way ANOVA: genotype 
[F1,58=1.526; P=0.222]; treatment [F1,58=0.101; P=0.752]; genotype x treatment [F1,58=0.0059; P=0.939]. 
Center: the total exploration time during the trial phase was slightly increased in vehicle-treated Ts65Dn 
mice compared to WT, however no significant difference was observed in Ts65Dn mice treated with DHF 
compared to WT. Two-way ANOVA: genotype [F1,58=3.301; P=0.074]; treatment [F1,58=8.720; P=0.005]; 
genotype x treatment [F1,58=5.193; P=0.026]. Right: the percentage of time spent exploring the three objects 
was not statistically different across groups. Two-way ANOVA on ranked transformed data: genotype 
[F1,174=0.110; P=0.741]; treatment [F1,174=1.396; P=0.228]; genotype x treatment [F1,174=1.141; 
P=0.340].The number in parenthesis indicate the number of mice tested for each experimental group. 
**p<0.01, Tukey post hoc test following two-way ANOVA. 
 
  
Supplementary Fig. 7 Full-length blot images corresponding to the cropped western blot presented in 
Figure 4, 5, 7 and Supplementary Figure 4. 
 
 
Supplementary Table 1. Primer sequences for RT-qPCR analysis. 
 
 
 
 
 
Gene symbol Gene name Organism Accession number Forward primer (5'-3') Reverse primer (5'-3') 
ACTB Actin beta Homo Sapiens NM_001101 CAGCAAGCAGGAGTATGAC GAAAGGGTGTAACGCAACT 
GAPDH 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
Homo 
Sapiens NM_001256799 AATGAAGGGGTCATTGATGG AAGGTGAAGGTCGGAGTCAA 
PPIA Peptidylprolyl isomerase A  
Homo 
Sapiens NM_021130 TTCTGCTGTCTTTGGGACCT CACCGTGTTCTTCGACATTG 
BDNF 
(CDS) 
Brain-derived 
neurotrophic factor 
Homo 
Sapiens 
NM_001143805 
NM_001143806 
NM_001143807 
NM_001143808 
NM_001143809 
NM_00114381 
NM_001143811 
NM_00114381 
NM_001143814 
NM_00114381 
NM_001709 
NM_170731 
NM_170732 
NM_170733 
NM_170734 
NM_170735 
CGAGACCAAGTGCAATCC TTATGAATCGCCAGCCAAT 
Actb Actin beta Mus Musculus NM_007393 AAGTGGTTACAGGAAGTCC ATAATTTACACAGAAGCAATGC 
Gapdh 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
Mus 
Musculus NM_008084 GAACATCATCCCTGCATCCA CCAGTGAGCTTCCCGTTCA 
Ppia Peptidylprolyl isomerase A  
Mus 
Musculus NM_008907 CACTGTCGCTTTTCGCCGCTTG TTTCTGCTGTCTTTGGAACTTTGTCTGC 
Bdnf 
(Exon I) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus NM_007540 TGGTAACCTCGCTCATTCATTAGA CCCTTCGCAATATCCGCAAAG 
Bdnf 
(Exon II) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus NM_001048139 CTTTTCCTCGCTGTCAAG TTGCCAAGAGTCTATTCC 
Bdnf 
(Exon III) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus NM_001285419 TCACGATCCTCGATGGATAGTTCT AGGGAGTGGAGCGCAGTC 
Bdnf 
(Exon IV) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus NM_001048141 CAAATGGAGCTTCTCGCTGAAGGC GTGGAAATTGCATGGCGGAGGTAA 
Bdnf 
(Exon V) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus NM_001285420 ACCATAACCCCGCACACTCTGT GCACCTTCCCGCACCACAAA 
Bdnf 
(Exon VI) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus NM_001048142 CTTCAACTGCCACCACTG CATTGTTGTCACGCTTCTG 
Bdnf 
(Exon VII) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus NM_001285417 GCTTACTTACAGGTCCAAGGTCAA GTCCTGGAGTTCCGCAGAC 
Bdnf 
(CDS) 
Brain-derived 
neurotrophic factor 
Mus 
Musculus 
NM_007540 
NM_001048139 
NM_001048141 
NM_001048142 
NM_001285416 
NM_001285417 
NM_001285418 
NM_001285419 
NM_001285420 
NM_001285421 
NM_001285422 
ATTACCTGGATGCCGCAAA TAATACTGTCACACACGCTCA 
Supplementary Table 2. Calibration curves parameters, PCR reaction efficiency and amplicon information 
for RT-qPCR analysis. 
Gene symbol Organism Amplicon 
length (bp) 
Final primer 
concentration 
(?M) 
Calibration curve  
(slope / R2) 
Calculated PCR 
efficiency (%) 
Primer dimers 
ACTB Homo Sapiens 91 0.2 -3.242 / 0.997 103.4 Not detected 
GAPDH Homo Sapiens 108 0.2 -3.493 / 0.999 93.3 Only in NTC samples 
PPIA Homo Sapiens 91 0.2 -3.446 / 0.997 95.1 Not detected 
BDNF 
(CDS) 
Homo Sapiens 149 0.2 -3.282 / 0.999 101.7 Not detected 
Actb Mus Musculus 123 0.1 -3.130 / 0.986 108.7 Not detected 
Gapdh Mus Musculus 77 0.2 -3.370 / 0.999 98.0 Only in NTC samples 
Ppia Mus Musculus 133 0.2 -3.321 / 0.994 100.0 Only in NTC samples 
Bdnf 
(Exon I) Mus Musculus 172 0.2 -3.450 / 0.999 94.9 Not detected 
Bdnf 
(Exon II) 
Mus Musculus 200 0.1 -3.175 / 0.998 106.5 Not detected 
Bdnf 
(Exon III) 
Mus Musculus 150 0.2 -3.716 / 0.994 85.3 Not detected 
Bdnf 
(Exon IV) 
Mus Musculus 57 0.2 -3.584 / 0.999 90.1 Not detected 
Bdnf 
(Exon V) 
Mus Musculus 73 0.2 -3.536 / 0.997 91.8 Not detected 
Bdnf 
(Exon VI) 
Mus Musculus 87 0.2 -3.573 / 0.999 90.5 Only in NTC samples 
Bdnf 
(Exon VII) Mus Musculus 93 0.2 -3.503 / 0.996 92.9 Not detected 
Bdnf 
(CDS) 
Mus Musculus 90 0.2 -3.315 / 0.999 100.3 Not detected 
 
 
 
 
 
 
 
 
 Supplementary Table 3. Human sample information. 
Case number Disorder Age (years) Gender 
1276 DS 13 M 
5277 DS 19 M 
M1960M DS 19 M 
5341 DS 25 M 
5005 DS 39 F 
4925 Control 13 M 
4782 Control 18 M 
1841 Control 19 M 
605 Control 25 M 
5606 Control 35 F 
 
 
 
Supplementary Table 4. List of mice used in the study. 
      Behavior IHC     
Mouse #  Genotype Treatment NOR OL CFC BrdU 24hr BrdU 4w VGAT/VGLUT1 EPhy EF Bioch 
1 WT sedentary *     *   *       
2 WT sedentary *     *           
3 WT sedentary *     *           
4 WT sedentary *     *           
5 WT sedentary *     *           
6 WT sedentary *     *   *       
7 WT sedentary *       *         
8 WT sedentary *       *         
9 WT sedentary *       *         
10 WT sedentary *       * * *     
11 WT sedentary *       * * *     
12 WT sedentary *       *         
13 WT sedentary *       * * *     
14 WT sedentary *       * * *     
15 WT sedentary *       *         
16 WT sedentary *       *         
17 WT sedentary *                 
18 WT sedentary *                 
19 WT sedentary *                 
20 WT sedentary *                 
21 WT sedentary *                 
22 WT sedentary *                 
23 WT sedentary *                 
24 WT sedentary *                 
25 WT sedentary *                 
26 WT sedentary *                 
27 WT sedentary *                 
28 WT sedentary *                 
29 WT sedentary     *             
30 WT sedentary     *             
31 WT sedentary     *             
32 WT sedentary     *             
33 WT sedentary     *             
34 WT sedentary     *             
35 WT sedentary     *             
36 WT sedentary     *             
37 WT sedentary     *             
38 WT sedentary     *             
39 WT sedentary     *             
40 WT sedentary     *             
41 WT sedentary     *             
42 WT sedentary     *             
43 WT sedentary   *               
44 WT sedentary   *               
45 WT sedentary   *               
46 WT sedentary   *               
47 WT sedentary   *               
48 WT sedentary   *               
49 WT sedentary   *               
50 WT sedentary   *               
51 WT sedentary   *               
52 WT sedentary   *               
53 WT sedentary   *               
54 WT sedentary   *               
55 WT sedentary   *               
56 WT sedentary   *               
57 WT sedentary   *               
58 WT sedentary   *               
59 WT sedentary   *               
60 WT sedentary   *               
61 WT sedentary   *               
62 WT sedentary   *               
63 WT sedentary   *               
64 WT sedentary               *   
65 WT sedentary               *   
66 WT sedentary               *   
67 WT sedentary               *   
68 WT sedentary               *   
69 WT sedentary               *   
70 WT sedentary               *   
71 WT sedentary               *   
72 WT sedentary               *   
73 WT sedentary               *   
74 WT sedentary 
              *   
75 WT sedentary 
              *   
76 WT sedentary 
              *   
77 WT sedentary 
              *   
78 WT sedentary 
              *   
79 WT sedentary 
              *   
80 WT sedentary                 * 
81 WT sedentary                 * 
82 WT sedentary                 * 
83 WT sedentary                 * 
84 WT sedentary                 * 
85 WT sedentary                 * 
86 WT sedentary                 * 
87 WT sedentary                 * 
88 WT sedentary                 * 
89 WT sedentary                 * 
90 WT sedentary                 * 
91 WT sedentary                 * 
92 Ts65Dn sedentary *     *           
93 Ts65Dn sedentary *     *   * *     
94 Ts65Dn sedentary *     *           
95 Ts65Dn sedentary *     *   *       
96 Ts65Dn sedentary *     *   * *     
97 Ts65Dn sedentary *     *           
98 Ts65Dn sedentary *     *   *       
99 Ts65Dn sedentary *       * * *     
100 Ts65Dn sedentary *       * * *     
101 Ts65Dn sedentary *       * *       
102 Ts65Dn sedentary *       * *       
103 Ts65Dn sedentary *       * *       
104 Ts65Dn sedentary *                 
105 Ts65Dn sedentary *                 
106 Ts65Dn sedentary *                 
107 Ts65Dn sedentary *                 
108 Ts65Dn sedentary *                 
109 Ts65Dn sedentary     *             
110 Ts65Dn sedentary     *             
111 Ts65Dn sedentary     *             
112 Ts65Dn sedentary     *             
113 Ts65Dn sedentary     *             
114 Ts65Dn sedentary     *             
115 Ts65Dn sedentary     *             
116 Ts65Dn sedentary   * *             
117 Ts65Dn sedentary   *               
118 Ts65Dn sedentary   *               
119 Ts65Dn sedentary   *               
120 Ts65Dn sedentary   *               
121 Ts65Dn sedentary   *               
122 Ts65Dn sedentary   *               
123 Ts65Dn sedentary   *               
124 Ts65Dn sedentary   *               
125 Ts65Dn sedentary   *               
126 Ts65Dn sedentary   *               
127 Ts65Dn sedentary   *               
128 Ts65Dn sedentary               *   
129 Ts65Dn sedentary               *   
130 Ts65Dn sedentary               *   
131 Ts65Dn sedentary               *   
132 Ts65Dn sedentary               *   
133 Ts65Dn sedentary               *   
134 Ts65Dn sedentary               *   
135 Ts65Dn sedentary               *   
136 Ts65Dn sedentary               *   
137 Ts65Dn sedentary               *   
138 Ts65Dn sedentary               *   
139 Ts65Dn sedentary               *   
140 Ts65Dn sedentary                 * 
141 Ts65Dn sedentary                 * 
142 Ts65Dn sedentary                 * 
143 Ts65Dn sedentary                 * 
144 Ts65Dn sedentary                 * 
145 Ts65Dn sedentary                 * 
146 Ts65Dn sedentary                 * 
147 Ts65Dn sedentary                 * 
148 Ts65Dn sedentary                 * 
149 Ts65Dn sedentary                 * 
150 Ts65Dn sedentary                 * 
151 Ts65Dn sedentary                 * 
152 WT exercise *     *           
153 WT exercise *     *           
154 WT exercise *     *           
155 WT exercise *     *   *       
156 WT exercise *     *           
157 WT exercise *     *           
158 WT exercise *     *   * *     
159 WT exercise *     *   *       
160 WT exercise *       * *       
161 WT exercise *       * *       
162 WT exercise *       *         
163 WT exercise *       *         
164 WT exercise   *     * * *     
165 WT exercise   *     * * *     
166 WT exercise   *     *         
167 WT exercise   *     *         
168 WT exercise   *     * * *     
169 WT exercise *                 
170 WT exercise *                 
171 WT exercise     *             
172 WT exercise     *             
173 WT exercise     *             
174 WT exercise     *             
175 WT exercise     *             
176 WT exercise     *             
177 WT exercise     *             
178 WT exercise     *             
179 WT exercise     *             
180 WT exercise     *             
181 WT exercise     *             
182 WT exercise     *             
183 WT exercise     *             
184 WT exercise     *             
185 WT exercise     *             
186 WT exercise     *             
187 WT exercise   *               
188 WT exercise   *               
189 WT exercise   *               
190 WT exercise   *               
191 WT exercise   *               
192 WT exercise   *               
193 WT exercise   *               
194 WT exercise   *               
195 WT exercise   *               
196 WT exercise   *               
197 WT exercise   *               
198 WT exercise   *               
199 WT exercise               *   
200 WT exercise               *   
201 WT exercise               *   
202 WT exercise               *   
203 WT exercise               *   
204 WT exercise               *   
205 WT exercise               *   
206 WT exercise               *   
207 WT exercise               *   
208 WT exercise               *   
209 WT exercise               *   
210 WT exercise               *   
211 WT exercise                 * 
212 WT exercise                 * 
213 WT exercise                 * 
214 WT exercise                 * 
215 WT exercise                 * 
216 WT exercise                 * 
217 WT exercise                 * 
218 WT exercise                 * 
219 WT exercise                 * 
220 WT exercise                 * 
221 WT exercise                 * 
222 WT exercise                 * 
223 Ts65Dn exercise *     *           
224 Ts65Dn exercise *     *           
225 Ts65Dn exercise *     *   *       
226 Ts65Dn exercise *     *           
227 Ts65Dn exercise *     *           
228 Ts65Dn exercise *     *   *       
229 Ts65Dn exercise *       * * *     
230 Ts65Dn exercise *       *         
231 Ts65Dn exercise   *     *         
232 Ts65Dn exercise *       * * *     
233 Ts65Dn exercise *       * * *     
234 Ts65Dn exercise   *     * * *     
235 Ts65Dn exercise   *     *         
236 Ts65Dn exercise *                 
237 Ts65Dn exercise *                 
238 Ts65Dn exercise *                 
239 Ts65Dn exercise *                 
240 Ts65Dn exercise *                 
241 Ts65Dn exercise *                 
242 Ts65Dn exercise *                 
243 Ts65Dn exercise     *             
244 Ts65Dn exercise     *             
245 Ts65Dn exercise     *             
246 Ts65Dn exercise     *             
247 Ts65Dn exercise     *             
248 Ts65Dn exercise     *             
249 Ts65Dn exercise     *             
250 Ts65Dn exercise     *             
251 Ts65Dn exercise     *             
252 Ts65Dn exercise   * *             
253 Ts65Dn exercise   * *             
254 Ts65Dn exercise   *               
255 Ts65Dn exercise   *               
256 Ts65Dn exercise   *               
257 Ts65Dn exercise   *               
258 Ts65Dn exercise   *               
259 Ts65Dn exercise   *               
260 Ts65Dn exercise   *               
261 Ts65Dn exercise   *               
262 Ts65Dn exercise               *   
263 Ts65Dn exercise               *   
264 Ts65Dn exercise               *   
265 Ts65Dn exercise               *   
266 Ts65Dn exercise               *   
267 Ts65Dn exercise               *   
268 Ts65Dn exercise               *   
269 Ts65Dn exercise               *   
270 Ts65Dn exercise               *   
271 Ts65Dn exercise               *   
272 Ts65Dn exercise               *   
273 Ts65Dn exercise               *   
274 Ts65Dn exercise                 * 
275 Ts65Dn exercise                 * 
276 Ts65Dn exercise                 * 
277 Ts65Dn exercise                 * 
278 Ts65Dn exercise                 * 
279 Ts65Dn exercise                 * 
280 Ts65Dn exercise                 * 
281 Ts65Dn exercise                 * 
282 Ts65Dn exercise                 * 
283 Ts65Dn exercise                 * 
284 Ts65Dn exercise                 * 
285 Ts65Dn exercise                 * 
286 WT vehicle *                 
287 WT vehicle *                 
288 WT vehicle *                 
289 WT vehicle *                 
290 WT vehicle *                 
291 WT vehicle *                 
292 WT vehicle *   *             
293 WT vehicle *   *             
294 WT vehicle *   *             
295 WT vehicle *   *             
296 WT vehicle *   *             
297 WT vehicle *   *             
298 WT vehicle *   *             
299 WT vehicle *   *             
300 WT vehicle *                 
301 WT vehicle *                 
302 WT vehicle *                 
303 WT vehicle   *               
304 WT vehicle   *               
305 WT vehicle   *               
306 WT vehicle   *               
307 WT vehicle   *               
308 WT vehicle   *               
309 WT vehicle   *               
310 WT vehicle   *               
311 WT vehicle   *               
312 WT vehicle   *               
313 WT vehicle   *               
314 WT vehicle   *               
315 WT vehicle   *               
316 WT vehicle   *               
317 WT vehicle   *               
318 WT vehicle   *               
319 WT vehicle               *   
320 WT vehicle               *   
321 WT vehicle               *   
322 WT vehicle               *   
323 WT vehicle               *   
324 WT vehicle               *   
325 WT vehicle                 * 
326 WT vehicle                 * 
327 WT vehicle                 * 
328 WT vehicle                 * 
329 WT vehicle                 * 
330 WT vehicle                 * 
331 WT vehicle                 * 
332 WT vehicle                 * 
333 WT vehicle                 * 
334 WT vehicle                 * 
335 WT vehicle                 * 
336 WT vehicle                 * 
337 WT vehicle (acute)                 * 
338 WT vehicle (acute)                 * 
339 WT vehicle (acute)                 * 
340 WT vehicle (acute)                 * 
341 WT vehicle (acute)                 * 
342 WT vehicle (acute)                 * 
343 WT vehicle (acute)                 * 
344 WT vehicle (acute)                 * 
345 WT vehicle (acute)                 * 
346 WT vehicle (acute)                 * 
347 WT vehicle (acute)                 * 
348 WT vehicle (acute)                 * 
349 WT vehicle (acute)                 * 
350 WT vehicle (acute)                 * 
351 WT vehicle (acute)                 * 
352 WT vehicle (acute)                 * 
353 Ts65Dn vehicle *   *             
354 Ts65Dn vehicle *   *             
355 Ts65Dn vehicle *   *             
356 Ts65Dn vehicle *   *             
357 Ts65Dn vehicle *   *             
358 Ts65Dn vehicle *   *             
359 Ts65Dn vehicle *   *             
360 Ts65Dn vehicle *   *             
361 Ts65Dn vehicle *                 
362 Ts65Dn vehicle   *               
363 Ts65Dn vehicle   *               
364 Ts65Dn vehicle   *               
365 Ts65Dn vehicle   *               
366 Ts65Dn vehicle   *               
367 Ts65Dn vehicle   *               
368 Ts65Dn vehicle   *               
369 Ts65Dn vehicle   *               
370 Ts65Dn vehicle   *               
371 Ts65Dn vehicle   *               
372 Ts65Dn vehicle   *               
373 Ts65Dn vehicle               *   
374 Ts65Dn vehicle               *   
375 Ts65Dn vehicle                 * 
376 Ts65Dn vehicle                 * 
377 Ts65Dn vehicle                 * 
378 Ts65Dn vehicle                 * 
379 Ts65Dn vehicle                 * 
380 Ts65Dn vehicle                 * 
381 Ts65Dn vehicle                 * 
382 Ts65Dn vehicle                 * 
383 Ts65Dn vehicle                 * 
384 Ts65Dn vehicle                 * 
385 Ts65Dn vehicle                 * 
386 Ts65Dn vehicle                 * 
387 Ts65Dn vehicle (acute)                 * 
388 Ts65Dn vehicle (acute)                 * 
389 Ts65Dn vehicle (acute)                 * 
390 Ts65Dn vehicle (acute)                 * 
391 Ts65Dn vehicle (acute)                 * 
392 Ts65Dn vehicle (acute)                 * 
393 Ts65Dn vehicle (acute)                 * 
394 Ts65Dn vehicle (acute)                 * 
395 Ts65Dn vehicle (acute)                 * 
396 Ts65Dn vehicle (acute)                 * 
397 Ts65Dn vehicle (acute)                 * 
398 Ts65Dn vehicle (acute)                 * 
399 Ts65Dn vehicle (acute)                 * 
400 Ts65Dn vehicle (acute)                 * 
401 Ts65Dn vehicle (acute)                 * 
402 Ts65Dn vehicle (acute)                 * 
403 WT DHF *                 
404 WT DHF *                 
405 WT DHF *                 
406 WT DHF *                 
407 WT DHF *                 
408 WT DHF *   *             
409 WT DHF *   *             
410 WT DHF *   *             
411 WT DHF *                 
412 WT DHF *   *             
413 WT DHF *   *             
414 WT  DHF *   *             
415 WT DHF *   *             
416 WT DHF *   *             
417 WT DHF *   *             
418 WT DHF *                 
419 WT DHF *                 
420 WT DHF *                 
421 WT DHF     *             
422 WT DHF   *               
423 WT DHF   *               
424 WT DHF   *               
425 WT DHF   *               
426 WT DHF   *               
427 WT DHF   *               
428 WT DHF   *               
429 WT DHF   *               
430 WT DHF   *               
431 WT DHF   *               
432 WT DHF   *               
433 WT DHF   *               
434 WT DHF   *               
435 WT DHF   *               
436 WT DHF   *               
437 WT DHF   *               
438 WT DHF   *               
439 WT DHF   *               
440 WT DHF               *   
441 WT DHF               *   
442 WT DHF               *   
443 WT  DHF               *   
444 WT DHF                 * 
445 WT DHF                 * 
446 WT DHF                 * 
447 WT DHF                 * 
448 WT DHF                 * 
449 WT DHF                 * 
450 WT DHF                 * 
451 WT DHF                 * 
452 WT DHF                 * 
453 WT DHF                 * 
454 WT DHF                 * 
455 WT DHF                 * 
456 WT DHF (acute)                 * 
457 WT DHF (acute)                 * 
458 WT DHF (acute)                 * 
459 WT DHF (acute)                 * 
460 WT DHF (acute)                 * 
461 WT DHF (acute)                 * 
462 WT DHF (acute)                 * 
463 WT DHF (acute)                 * 
464 WT DHF (acute)                 * 
465 WT DHF (acute)                 * 
466 WT DHF (acute)                 * 
467 WT DHF (acute)                 * 
468 WT DHF (acute)                 * 
469 WT DHF (acute)                 * 
470 WT DHF (acute)                 * 
471 WT DHF (acute)                 * 
472 WT DHF (acute)                 * 
473 WT DHF (acute)                 * 
474 WT DHF (acute)                 * 
475 WT DHF (acute)                 * 
476 Ts65Dn DHF *                 
477 Ts65Dn DHF *                 
478 Ts65Dn DHF *                 
479 Ts65Dn DHF *                 
480 Ts65Dn DHF *                 
481 Ts65Dn DHF *                 
482 Ts65Dn DHF *                 
483 Ts65Dn DHF *                 
484 Ts65Dn DHF *   *             
485 Ts65Dn DHF *   *             
486 Ts65Dn DHF *   *             
487 Ts65Dn DHF *   *             
488 Ts65Dn DHF *   *             
489 Ts65Dn DHF *   *             
490 Ts65Dn DHF *   *             
491 Ts65Dn DHF *                 
492 Ts65Dn DHF *                 
493 Ts65Dn DHF *                 
494 Ts65Dn DHF   *               
495 Ts65Dn DHF   *               
496 Ts65Dn DHF   *               
497 Ts65Dn DHF   *               
498 Ts65Dn DHF   *               
499 Ts65Dn DHF   *               
500 Ts65Dn DHF   *               
501 Ts65Dn DHF   *               
502 Ts65Dn DHF   *               
503 Ts65Dn DHF   *               
504 Ts65Dn DHF   *               
505 Ts65Dn DHF               *   
506 Ts65Dn DHF               *   
507 Ts65Dn DHF               *   
508 Ts65Dn DHF                 * 
509 Ts65Dn DHF                 * 
510 Ts65Dn DHF                 * 
511 Ts65Dn DHF                 * 
512 Ts65Dn DHF                 * 
513 Ts65Dn DHF                 * 
514 Ts65Dn DHF                 * 
515 Ts65Dn DHF                 * 
516 Ts65Dn DHF                 * 
517 Ts65Dn DHF                 * 
518 Ts65Dn DHF                 * 
519 Ts65Dn DHF                 * 
520 Ts65Dn DHF (acute)                 * 
521 Ts65Dn DHF (acute)                 * 
522 Ts65Dn DHF (acute)                 * 
523 Ts65Dn DHF (acute)                 * 
524 Ts65Dn DHF (acute)                 * 
525 Ts65Dn DHF (acute)                 * 
526 Ts65Dn DHF (acute)                 * 
527 Ts65Dn DHF (acute)                 * 
528 Ts65Dn DHF (acute)                 * 
529 Ts65Dn DHF (acute)                 * 
530 Ts65Dn DHF (acute)                 * 
531 Ts65Dn DHF (acute)                 * 
532 Ts65Dn DHF (acute)                 * 
533 Ts65Dn DHF (acute)                 * 
534 Ts65Dn DHF (acute)                 * 
535 Ts65Dn DHF (acute)                 * 
536 Ts65Dn DHF (acute)                 * 
537 Ts65Dn DHF (acute)                 * 
538 Ts65Dn DHF (acute)                 * 
539 Ts65Dn DHF (acute)                 * 
 
Asterisk indicates the experimental procedure/test carried out on each mouse.  
NOR: Novel Object Recognition test. OL: Object Location test. CFC: Contextual Fear Conditioning test. 
IHC: Immunohistochemistry. EM: Electron Microscopy. EPhy: Electrophysiology. Bioch: Biochemistry.  
Mice highlighted in yellow did perform the NOR or OL behavioral tests, but could not be included in the 
study because we lost the video-recording files of the behavioral tests due to the failure of a hard-drive in 
which they were stored. Files could not be recovered. 
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